Direct Connective Synthesis of 5,5-Disubstituted Hydantoins by Tandem α-Amination and α-Arylation of Silyl Enol Ethers

Rakesh K. Saunthwal, Matthew T. Cornall, John W. Ward* and Jonathan Clayden*

School of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS (UK) E-mail: john.ward@liverpool.ac.uk; j.clayden@bristol.ac.uk

Contents

1 Experimental	
1.1 General Directions	2-2
1.2 Analytical Directions	2-3
1.3 Literature Known Starting Materials	3-3
1.4 General scheme for Starting materials preparation	3-3
1.5 General Procedure 1: Carbamoyl Chloride Synthesis from the secondary amines and analytical data	4-5
1.6 General Procedure 2: Synthesis of Symmetrical arylhydrazine-1,2-dicarboxamide	5-16
1.7 General Procedure 3: Synthesis of Symmetrical α , β unsaturated azocarbonamides	6-16
1.8 General Procedure 4: Carbamoyl Chloride and tert-Butyl carbamate coupling	16-29
1.9 General Procedure 5: Synthesis of unsymmetrical α , β unsaturated azocarbonamides	16-29
1.10 General Procedure 6: Synthesis of Silyl enol ether	29-33
1.11 X-ray crystallography	33-34
1.12 ReactIR studies	35-35
1.13 Procedures and Analytical data of Urea substituted hydantoins (4)	36-46
1.14 General Procedure 7: Synthesis of Boc-hyantoins (7)	46-46
1.15 Procedure and Analytical data of hydantoins	47-69
1.16 General procedure 8: Benzyl deprotection	69-69
1.17 General Procedure 9: Boc-group deprotection:	69-71
1.18 General Procedure 9: Synthesis of bioactive compound analogues	71-73
1.19 ¹ H and ¹³ C NMR Spectra	74-243

1 Experimental

1.1 General Directions: Reactions requiring anhydrous conditions (where specified) were executed under dry nitrogen or argon atmospheres in glassware that was dried using either a combination of vacuum and heat-gun, oven, or flame drying. Reaction mixtures were stirred magnetically. Air- and moisture-sensitive liquids and solutions were transferred via syringe into the reaction vessels through rubber septa. Reactions run in a microwave oven were completed on a Biotage Initiator+. All reagents were purchased (unless specified) at highest commercial quality and used as received. Non-anhydrous solvents were purchased (unless specified) at the highest commercial quality and used as received. Anhydrous CH_2Cl_2 and THF were obtained from the University of Bristol's dry solvent system and were purified by filtration over a column of activated alumina. All temperatures described below -10 °C were achieved using a Julabo cryostat

1.2 Analytical Directions

Rf: TLC was performed on aluminium backed silica plates (0.2 mm, 60 F254) which were developed using standard visualising agents: UV fluorescence (254 & 366 nm), phosphomolybdic acid / Δ , vanillin / Δ , potassium permanganate / Δ and Seebach / Δ . Chromatography: Flash chromatography was performed on an automated Biotage Isolera TM Spectra Four using gradient elution on pre-packed silica gel Biotage® SNAP Ultra columns.

MP: Melting points were measured on a Kofler hotstage melting point apparatus and are uncorrected.

IR: IR spectra were recorded on neat compounds using a Perkin Elmer (Spectrum One) FT-IR spectrometer (ATR sampling accessory). Only strong and selected absorbance's (*v*max expressed in cm⁻¹) are reported.

¹**H NMR:** Spectra were recorded on Jeol ECS (400 MHz) or Bruker NMR (400 MHz or 500 MHz) instruments. Chemical shifts (δ H) are quoted in parts per million (ppm) was

used. Spin-spin coupling constants (*J*) are reported in Hertz (Hz). 2D NMR experiments HSQC and HMBC where necessary. Spin-spin coupling constants (J) are reported in Hertz (Hz)


¹³C NMR: Spectra were recorded on Jeol ECS (101 MHz) or Bruker NMR (101 MHz or 125 MHz) instruments. Chemical shifts (δ C) are quoted in parts per million (ppm) and referenced to the appropriate solvent peak(s). Spin-spin coupling constants (*J*) are reported in Hertz (Hz).

HRMS: High resolution mass spectra were recorded on a Bruker Daltronics MicrOTOF 2 mass spectrometer (ESI).

1.3 Literature Known Starting Materials¹

Starting materials carbamoyl chlorides were prepared according to the procedures reported, Spectroscopic data for the materials prepared as described above were consistent with those reported in the literature.

1.4 General scheme for Starting materials preparation



¹ (a) F. Fernández-Nieto, J. Mas Roselló, S. Lenoir, S. Hardy, J. Clayden, *Org. Lett.* **2015**, *17*, 3838-3841 (b) R. C. Atkinson, F. Fernández-Nieto, J. Mas Roselló, J. Clayden, *Angew. Chemie Int. Ed.* **2015**, *54*, 8961-8965 (c) R. C. Atkinson, D. J. Leonard, J. Maury, D. Castagnolo, N. Volz, J. Clayden, *Chem. Commun.* **2013**, *49*, 9734-9736. (d) J. Maury, J. Clayden, *J. Org. Chem.* **2015**, *80*, 10757-10768

1.5 General Procedure 1: Carbamoyl Chloride Synthesis from the secondary Amines

A flame-dried two-necked round bottom flask was allowed to cool to RT under vacuum. Triphosgene (0.46 equiv) was then added and the reaction vessel subsequently nitrogen/vacuum cycled three times. Anhydrous CH_2Cl_2 (0.7 M) was then added under an atmosphere of nitrogen and the reaction was cooled to 0 °C. Pyridine (1 equiv was then added dropwise and the reaction allowed to stir for 5 min at 0 °C. Aniline (1 equiv) was then added to the reaction mixture dropwise and allowed to stir for 5 min. The reaction mixture was then allowed to warm to RT until consumption of the aniline was observed by TLC. The reaction mixture was quenched with HCl (1 M, 3 × 20 mL) and extracted with CH_2Cl_2 (3 x 20 mL). The combined organic phases were washed with sat. NaHCO₃ (20 mL), dried over MgSO₄, filtered and the subsequent filtrate concentrated under vacuum to yield the crude carbamoyl chloride. Purification through a pad of silica eluting with 10% EtOAc/Petrol (200 mL) gave the desired carbamoyl chloride, which could be used directly in the next step or stored in the freezer at -20 °C until required. (N.B. prior to purification the carbamoyl chlorides often have vibrant colours. Some of the carbamoyl chlorides solidify on standing at -20 °C).



V_{max} /cm⁻¹(neat): 2987, 1732, 1322, 1120, 698

Methyl(3-(trifluoromethyl)phenyl)carbamic chloride (S1f) ¹H NMR (400 MHz; CDCl₃) δ 7.67–7.57 (m, 3H), 7.51–7.49 (m, 1H), 3.45 (s, 3H); ¹³C NMR (101 MHz; CDCl₃) δ 148.8, 143.5, 132.3 (q, J_{C-F} = 33.0 Hz), 131.0 (br), 130.3, 125.3 (br), 124.6 (br), 123.4 (q, J_{C-F} = 272.6.0 Hz), 40.3; **HRMS** (ESI) calcd for [C₉H₇ClF₃NONa] requires [M + Na]+ 260.0066, found 260.0059



*V*_{max} /cm⁻¹(neat): 2976, 1728, 1401, 1233, 773

Methyl(naphthalen-1-yl)carbamic chloride (S5i) (colourless Semi-solid) ¹**H NMR** (400 MHz; CDCl₃) δ 7.92 (dd, J = 7.9, 4.0 Hz, 2H), 7.85 (d, J = 8.7 Hz, 1H), 7.64 – 7.47 (m, 3H), 7.38 (d, J = 7.3 Hz, 1H), 4.17 (dq, J = 14.2, 7.2 Hz, 1H), 3.59 (dt, J = 13.6, 6.9 Hz, 1H), 1.26 (t, J = 7.2 Hz, 3H); ¹³**C NMR** (101 MHz; CDCl₃) δ 149.8, 137.8, 134.7, 130.2, 129.4, 128.7, 127.6, 126.8, 125.5, 122.3, 48.07, 13.2; **HRMS** (ESI) calcd for [C₁₃H₁₂C1NONa] requires [M + Na]+ 256.0505, found 256.0494

 V_{max} /cn⁻¹(neat): 2945, 1735, 1481, 1351, 1267, 1059,


(2-Chlorophenyl)(methyl)carbamic chloride (S5j), ¹H NMR (400 MHz; CDCl₃) δ 7.51 – 7.46 (m, 1H), 7.36 – 7.29 (m, 3H), 3.30 (s, 3H). ¹³C NMR (101 MHz; CDCl₃) δ 149.3, 140.4, 133.0, 130.6, 130.3, 129.8, 128.2, 38.9. HRMS (ESI) calcd for [C₈H₇C1₂NONa] requires [M + Na]+ 225.9802, found 225.9797

1.6 General Procedure 2: Synthesis of Symmetrical arylhydrazine-1,2-dicarboxamide:

A solution of arylcarbamic chloride (1.0 equiv) in MeCN (1.5 M) was added dropwise to a solution of hydrazine monohydrate (1 equiv) in EtOH (1.5 M) at 0 °C. After 10 minutes a solution of arylcarbamic chloride (1.0 equiv) in MeCN (1.5 M) and a solution of Na₂CO₃ (1 equiv) in H₂O (0.75 M) were added to the reaction flask simultaneously. The resulting solution was stirred at room temperature for 20 h, giving a precipitate. The reaction was concentrated under reduced pressure, re-dissolved in DCM, filtered and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography afforded the title compound.

1.7 General Procedure 3: Synthesis of Symmetrical α, β unsaturated azocarbonamides

A solution of *N*-bromosuccinimide (1.2-1.5 equiv) in DCM (0.15 M) was added dropwise to a solution of pyridine (2 equiv) and arylhydrazine-1,2-dicarboxamide **S1** in DCM (11 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3×20 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography afforded the s an orange solid.




 N^{1} , N^{2} -dimethyl- N^{1} , N^{2} -diphenylhydrazine-1,2-dicarboxamide (S1a). A solution of methyl(phenyl)carbamic chloride (750 mg, 4.4 mmol) in MeCN (2.9 mL, 1.5 M) was added dropwise to a solution of hydrazine monohydrate (142 mg, 4.4 mmol, 1 equiv) in EtOH (2.9 mL, 1.5 M) at 0 °C. After 10 minutes a solution of methyl(phenyl)carbamic chloride (750 mg, 4.4 mmol) in MeCN (2.9 mL, 1.5 M) and a solution of $Na_{2}CO_{3}$ (465 mg 4.4 mmol) in H₂O (5.8 mL, 0.75 M) were added to the reaction flask simultaneously. The resulting solution was stirred at room temperature for 20 h, giving a precipitate. The reaction was concentrated under reduced pressure, re-dissolved in DCM, filtered and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (5% MeOH/DCM) afforded the title compound (1013 mg, 75%) as a white solid.

MP: 145-147 °C

*V*_{max} /cm⁻¹(neat): 3287, 2922, 1662, 1512, 1476, 1335, 1138, 824

¹**H NMR** (400 MHz; CDCl₃) δ 7.42 (d, J = 8.3 Hz, 2H), 7.40 – 7.35 (m, 6H), 7.29 (tt, J = 6.1, 1.6 Hz, 2H), 6.06 (s, 2H), 3.27 (s, 6H); ¹³**C NMR** (101 MHz; CDCl₃) δ ¹³**C** NMR (101 MHz,

CDCl₃) δ 159.2, 142.3, 130.0, 127.6, 127.2, 37.4; **HRMS m/z** (ESI⁺) [C₁₆H₁₈N₄O₂Na] requires [M + Na]+: 321.1327; found: 321.1320




(*E*)-N¹,N²-dimethyl-N¹,N²-diphenyldiazene-1,2-dicarboxamide (1a). A solution of *N*bromosuccinimide (356 mg, 2.23 mmol, 1.2 eq.) in DCM (11 mL, 0.15 M) was added dropwise to a solution of pyridine (0.30 mL, 3.3 mmol, 2 eq.) and N¹,N²-dimethyl-N¹,N²diphenylhydrazine-1,2-dicarboxamide S1a (500 mg, 1.67 mmol) in DCM (5.5 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3×20 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (10% EtOAc/Hexane) afforded *the title compound* (372 mg, 75%) as an orange solid.

MP: 171-173 °C

*V*_{max} /cm⁻¹(neat): 2921, 1710, 1705, 1574, 1362,

¹**H NMR** (400 MHz, CDCl₃) δ 7.39 – 7.24 (m, 10H), 3.39 (s, 6H); ¹³**C NMR** (100 MHz, CDCl3) δ ¹³**C** NMR (101 MHz, CHLOROFORM-*D*) δ 160.9, 140.6, 129.4, 128.0, 127.1, 38.5; HRMS (ESI) calcd for [C₁₆H₁₆N₄O₂Na] requires [M + Na]+ 319.1171, found 319.1164




N¹, N²-dimethyl-N¹, N²-di-*p*-tolylhydrazine-1,2-dicarboxamide (S1b). A solution of *N*-methyl(*p*-tolyl)carbamic chloride (750 mg, 4.09 mmol) in MeCN (2.73 mL, 1.5 M) was added dropwise to a solution of hydrazine monohydrate (131 mg, 4.09 mmol, 1 equiv) in EtOH (2.73 mL, 1.5 M) at 0 °C. After 10 minutes a solution of *N*-methyl(*p*-tolyl)carbamic chloride (750 mg, 4.09 mmol) in MeCN (2.73 mL, 1.5 M) and a solution of Na₂CO₃ (430 mg 4.09 mmol) in H₂O (5.46 mL, 0.75 M) were added to the reaction flask simultaneously. The resulting solution

was stirred at room temperature for 20 h, giving a precipitate. The reaction was concentrated under reduced pressure, re-dissolved in DCM, filtered and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (5% MeOH/DCM) afforded the title compound (1023 mg, 76%) as a white solid.

MP: 150-152 °C

*V*_{max} /cm⁻¹(neat): 3287, 2922, 1662, 1512, 1476, 1335, 1138, 824

¹**H NMR** (400 MHz; CDCl₃) δ 7.25 – 7.22 (m, 4H), 7.20 – 7.17 (m, 4H), 6.04 (br, s, 2H), 3.23 (s, 6H), 2.23 (s, 6H); ¹³**C NMR** (101 MHz; CDCl₃) δ 158.0, 139.6, 137.9, 130.8, 127.1, 37.7, 21.2; **HRMS m/z** (ESI⁺) [C₁₈H₂₂N₄O₂Na] requires [M + Na]+: 349.1640; found: 349.1644



(*E*)-N¹,N²-dimethyl-N¹,N²-di-*p*-tolyldiazene-1,2-dicarboxamide (1b); A solution of *N*bromosuccinimide (651 mg, 3.68 mmol, 1.2 equiv) in DCM (20 mL, 0.15 M) was added dropwise to a solution of pyridine (0.557 mL, 6.12 mmol, 2 equiv) and N¹,N²-dimethyl-N¹,N²di-*p*-tolylhydrazine-1,2-dicarboxamide **S1b** (1g, 3.06 mmol) in DCM (10 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3 × 20 mL). The combined organics were washed with brine (1 × 20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAc/Hexane) afforded the title compound (876 mg, 88%) as orange needles.

MP: 181-183 °C


 V_{max} /cm⁻¹(neat): 2922, 1709, 1572, 1365, 1125, 820, 555 ¹H NMR (400 MHz, CDCl₃) δ 7.12 (d, J = 8.0 Hz, 4H), 6.86 (d, J = 8.0 Hz, 4H), 3.37 (s, 6H) 2.34 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 161.1, 138.1, 137.9, 130.0, 126.9, 38.6, 21.2; HRMS (ESI) calcd for [C₁₈H₂₀N₄O₂ Na] requires [M + Na]+ 347.1484, found 347.1477 NC O H Me N N N N N N Me O

 N^1 , N^2 -bis(4-cyanophenyl)- N^1 , N^2 -dimethylhydrazine-1, 2-dicarboxamide (S1c). A solution of (4-cyanophenyl)(methyl)carbamic chloride (400 mg, 2.06 mmol) in MeCN (1.37 mL, 1.5 M) was added dropwise to a solution of hydrazine monohydrate (65 mg, 2.03 mmol, 1 equiv) in EtOH (1.37 mL, 1.5 M) at 0 °C. After 10 minutes a solution of (4cyanophenyl)(methyl)carbamic chloride (400 mg, 2.06 mmol) in MeCN (1.37 mL, 1.5 M) and a solution of Na₂CO₃ (259 mg 2.47 mmol) in H₂O (2.74 mL, 0.75 M) were added to the reaction flask simultaneously. The resulting solution was stirred at room temperature for 20 h, giving a precipitate. The reaction was concentrated under reduced pressure, re-dissolved in DCM, filtered and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (5% MeOH/DCM) afforded the title compound (509 mg, 71%) as a white solid.

MP: 200-202 °C

*V*_{max} /cm⁻¹(neat): 3320, 2970, 2227, 1665, 1603, 1505, 1333, 1110, 754

¹H NMR (400 MHz; CDCl₃) δ 7.76 – 7.73 (m, 4H), 7.59 – 7.56 (m, 4H), 6.33 (br, s, 2H), 3.36 (s, 6H); ¹³C NMR (101 MHz; CDCl₃) δ 156.9, 146.5, 133.9, 127.0, 118.0, 110.8, 37.4; HRMS m/z (ESI⁺) [C₁₈H₁₆N₆O₂Na] requires [M + Na]+: 371.1232; found: 371.1243




(*E*)-N¹,N²-bis(4-cyanophenyl)-N¹,N²-dimethyldiazene-1,2-dicarboxamide (1c); A solution of *N*-bromosuccinimide (305 mg, 1.7 mmol, 1.2 equiv) in DCM (9.4 mL, 0.15 M) was added dropwise to a solution of pyridine (0.260 mL, 2.8 mmol, 2 equiv) and N¹,N²-bis(4-cyanophenyl)-N¹,N²-dimethylhydrazine-1,2-dicarboxamide **S1c** (500, 1.4 mmol) in DCM (4.7 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat.

aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3×20 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAc/Hexane) afforded the *title compound* (420 mg, 84%) as orange needles.

MP: 204-206 °C

*V*_{max} /cm⁻¹(neat): 3398, 2312, 1720, 1658, 1023, 995

¹H NMR (500 MHz, CDCl₃) δ 7.66 (d, J = 8.6 Hz, 4H), 7.25 – 7.15 (m, 4H), 3.46 (s, 6H);
¹³C NMR (126 MHz, CDCl₃)160.0, 144.3, 133.3, 127.4, 117.7, 111.8, 29.7; HRMS (ESI) calcd for [C₁₈H₁₄N₆O₂Na] requires [M + Na]+ 369.1076, found 369.1070




 N^{1} , N^{2} -bis(4-fluorophenyl)- N^{1} , N^{2} -dimethylhydrazine-1,2-dicarboxamide (S1d); A solution of (4-fluorophenyl)(methyl)carbamic chloride (500 mg, 2.67 mmol) in MeCN (1.78 mL, 1.5 M) was added dropwise to a solution of hydrazine monohydrate (85 mg, 2.65 mmol, 1 equiv) in EtOH (1.78 mL, 1.5 M) at 0 °C. After 10 minutes a solution of (4-fluorophenyl) (methyl)carbamic chloride (500 mg, 2.67 mmol) in MeCN (1.5 mL, 1.5 M) and a solution of Na₂CO₃ (245 mg 2.3 mmol) in H₂O (3.5 mL, 0.75 M) were added to the reaction flask simultaneously. The resulting solution was stirred at room temperature for 20 h, giving a precipitate. The reaction was concentrated under reduced pressure, re-dissolved in DCM, filtered and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (05% MeOH/DCM) afforded the title compound (630 mg, 70%) as a white solid.

MP: 100-102 °C

*V*_{max} /cm⁻¹(neat): 3286, 2967, 1786, 1660, 1505, 1338, 1220, 1140, 842, 752

¹**H** NMR (400 MHz; CDCl₃) δ 7.36 – 7.33 (m, 4H), 7.11 – 7.07 (m, 4H), 6.00 (br, s, 2H), 3.23 (s, 6H); ¹³**C** NMR (101 MHz; CDCl₃) δ 161.0 (d, *J*_{*C*-*F*} = 249.0 Hz), 157.9, 138.1, 129.2 (d, *J*_{*C*-*F*} = 8.0 Hz), 117.2 (d, *J*_{*C*-*F*} = 23.2 Hz), 37.9; HRMS m/z (ESI⁺) [C₁₆H₁₆F₂N₄O₂Na] requires [M+Na]⁺ 357.1139; found: 357.1136




(*E*)-N¹,N²-bis(4-fluorophenyl)-N¹,N²-dimethyldiazene-1,2-dicarboxamide (1d); A solution of *N*-bromosuccinimide (381 mg, 2.15 mmol, 1.2 equiv) in DCM (11.9 mL, 0.15 M) was added dropwise to a solution of pyridine (0.32 mL, 3.5 mmol, 2 equiv) and N¹,N²-bis(4-fluorophenyl)-N¹,N²-dimethylhydrazine-1,2-dicarboxamide **S1d** (250 mg, 0.89 mmol) in DCM (5.56 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 5 h, before being quenched with sat. aq. NaHCO₃ (20 mL) and the aqueous layer was extracted with DCM (3 × 20 mL). The combined organics were washed with brine (1 × 20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAc/Hexane) afforded the title compound (550 mg, 92%) as orange needles.

MP: 161-163 °C

*V*_{max} /cm⁻¹(neat): 2986, 1713, 1507, 1370, 1222, 842

¹**H** NMR (400 MHz, CDCl₃) δ 7.07-6.99 (m, 8H), 3.41 (s, 6H); ¹³**C** NMR (100 MHz, CDCl₃) δ 161.2 (d, $J_{C-F} = 219.0$ Hz), 160.5, 136.5, 128.9 (d, $J_{C-F} = 9.0$ Hz), 116.4 (d, $J_{C-F} = 23.2.0$ Hz), 38.9; HRMS (ESI) calcd for [C₁₆H₁₄F₂N₄O₂Na] requires [M + Na]+ 355.0983, found 355.0985



 N^1 , N^2 -bis(3-chlorophenyl)- N^1 , N^2 -dimethylhydrazine-1,2-dicarboxamide (S1e); A solution of (3-chlorophenyl)(methyl)carbamic chloride (400 mg, 1.98 mmol) in MeCN (1.3 mL, 1.5 M) was added dropwise to a solution of hydrazine monohydrate (63 mg, 1.98 mmol, 1 equiv) in EtOH (1.3 mL, 1.5 M) at 0 °C. After 10 minutes a solution of (4fluorophenyl)(methyl)carbamic chloride (500 mg, 2.67 mmol) in MeCN (1.3 mL, 1.5 M) and a solution of Na₂CO₃ (207 mg 1.98 mmol) in H₂O (3.0 mL, 0.75 M) were added to the reaction flask simultaneously. The resulting solution was stirred at room temperature for 20 h, giving a precipitate. The reaction was concentrated under reduced pressure, re-dissolved in DCM, filtered and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (05% MeOH/DCM) afforded the title compound (600 mg, 82%) as white needles.

MP: 164-166 °C

*V*_{max} /cm⁻¹(neat): 3280, 2969, 1660 1591, 1479, 1351

¹**H** NMR (400 MHz; CDCl₃) δ 7.35 (dd, J = 4.9, 2.9 Hz, 3H), 7.32 – 7.30 (m, 2H), 7.28 (dt, J = 3.6, 1.8 Hz, 2H), 7.27 – 7.24 (m, 1H), 6.13 (s, 2H), 3.25 (s, 6H); ¹³C NMR (101 MHz; CDCl₃) δ 157.41, 143.47, 135.53, 131.15, 128.11, 127.47, 125.41, 37.74; **HRMS m/z** (ESI⁺) [C₁₆H₁₆Cl₂N₄O₂Na] requires [M+Na]⁺ 389.0548; found: 389.0548

(*E*)-N¹,N²-bis(3-chlorophenyl)-N¹,N²-dimethyldiazene-1,2-dicarboxamide(1e); A solution of *N*-bromosuccinimide (402 mg, 2.2 mmol, 1.2 equiv) in DCM (12.6 mL, 0.15 M) was added dropwise to a solution of pyridine (0.34 mL, 3.7 mmol, 2 equiv) and N¹,N²-bis(3-chlorophenyl)-N¹,N²-dimethylhydrazine-1,2-dicarboxamide **S1e** (690 mg, 1.89 mmol) in DCM (6.3 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 5 h, before being quenched with sat. aq. NaHCO₃ (20 mL) and the aqueous layer was extracted with DCM (3 × 20 mL). The combined organics were washed with brine (1 × 20 mL), dried over MgSO₄ and

concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (10% EtOAc/Hexane) afforded the title compound (620 mg, 90%) as orange needles.

MP: 116-118 °C *V*_{max} /cm⁻¹(neat): 2987, 1713, 1364, 786, 693 ¹**H NMR** (400 MHz, CDCl₃) δ 7.28 (d, *J* = 4.0 Hz, 5H), 7.08 (s, 2H), 6.87 (s, 1H), 3.40 (s,


6H); ¹³C NMR (100 MHz, CDCl3) δ 160.4, 141.7, 135.0, 130.5, 128.4, 127.1, 125.6, 125.2, 38.6; HRMS (ESI) calcd for [C₁₆H₁₄Cl₂N₄O₂Na] requires [M + Na]+ 387.0392, found 387.0389

 N^{1} , N^{2} -dimethyl- N^{1} , N^{2} -bis(3-(trifluoromethyl)phenyl)hydrazine-1,2-dicarboxamide(S1f). A solution of methyl(3-(trifluoromethyl)phenyl)carbamic chloride (400 mg, 1.68 mmol) in MeCN (1.1 mL, 1.5 M) was added dropwise to a solution of hydrazine monohydrate (85 mg, 2.65 mmol, 1 equiv) in EtOH (1.1 mL, 1.5 M) at 0 °C. After 10 minutes a solution of methyl(3-(trifluoromethyl)phenyl)carbamic chloride (400 mg, 1.68 mmol) in MeCN (1.1 mL, 1.5 M) and a solution of Na₂CO₃ (212 mg 2.0 mmol) in H₂O (2.2 mL, 0.75 M) were added to the reaction flask simultaneously. The resulting solution was stirred at room temperature for 20 h, giving a precipitate. The reaction was concentrated under reduced pressure, re-dissolved in DCM, filtered and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (5% MeOH/DCM) afforded the title compound (663 mg, 90%) as white needles.

MP: 112-114 °C

*V*_{max} /cm⁻¹(neat): 3274, 2968, 1658, 1613, 1593, 1492, 1327, 1120, 701

¹**H** NMR (400 MHz; CDCl₃) δ 7.65 – 7.63 (m, 2H), 7.60 – 7.55 (m, 6H), 6.09 (br, s, 1H), 3.31 (s, 6H); ¹³C NMR (101 MHz; CDCl₃) δ 157.3, 142.9, 132.8, 132.4, 130.8, 130.6, 126.0 (q, *J*_C-*F* = 272 Hz), 124.5 (q, *J*_{C-F} = 4.0 Hz, CF₃), 123.9 (d, *J*_{C-F} = 4.0 Hz, CF₃), 37.7; **HRMS m/z** (ESI⁺) [C₁₈H₁₆F₆N₄O₂Na] requires[M + Na]+: 457.1075; found: 457.1057




(*E*)-N¹,N²-dimethyl-N¹,N²-bis(3-(trifluoromethyl)phenyl)diazene-1,2-dicarboxamide(1f); A solution of *N*-bromosuccinimide (244.7 mg, 1.38 mmol, 1.2 equiv) in DCM (7.6 mL, 0.15 M) was added dropwise to a solution of pyridine (0.20 mL, 2.3 mmol, 2 equiv) and N¹,N²-dimethyl-N¹,N²-bis(3-(trifluoromethyl)phenyl)hydrazine-1,2-dicarboxamide **S1f** (500 mg, 1.15 mmol) in DCM 3.8 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 5 h, before being quenched with sat. aq. NaHCO₃ (20 mL) and the aqueous layer was extracted with DCM (3 × 20 mL). The combined organics were washed with brine (1 × 20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAc/Hexane) afforded the title compound (420 mg, 84%) as orange needles.

MP: 143-145 °C

*V*_{max} /cm⁻¹(neat): 2936, 1718, 1709 1452, 1328, 1121, 1071, 699

¹**H NMR** (400 MHz, CDCl₃) δ 7.57-7.33 (m, 7H), 7.19-7.13 (m, 1H), 3.44 (s, 6H); ¹³**C NMR** (100 MHz, CDCl₃) δ 160.1, 141.4, 132.2 (d, $J_{C-F} = 33.4$ Hz), 130.6, 130.10, 124.9, (d, $J_{C-F} = 23.0$ Hz), 123.3 (q, $J_{C-F} = 272.7$ Hz), 121.7 (d, $J_{C-F} = 22.0$ Hz), 38.6; HRMS (ESI) calcd for [C₁₈H₁₄F₆N₄O₂Na] requires [M + Na]+ 455.0919, found 455.0903



N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)hydrazine-1,2-dicarboxamide (S1g). A solution of N-methyl(pyridin-2-yl)carbamic chloride (400 mg, 2.35 mmol) in MeCN (1.56 mL, 1.5 M)

was added dropwise to a solution of hydrazine monohydrate (75mg, 2.3 mmol, 1 equiv) in EtOH (1.56 mL, 1.5 M) at 0 °C. After 10 minutes a solution of N-methyl(pyridin-2-yl)carbamic chloride (400 mg, 2.35 mmol) in MeCN (1.56 mL, 1.5 M) and a solution of Na₂CO₃ (247 mg 2.3 mmol) in H₂O (3.1 mL, 0.75 M) were added to the reaction flask simultaneously. The resulting solution was stirred at room temperature for 20 h, giving a precipitate. The reaction was concentrated under reduced pressure, re-dissolved in DCM, filtered and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (2% MeOH/DCM) afforded the title compound (560 mg, 79%) as a pale white solid.

MP: 160-162 °C

*V*_{max} /cm⁻¹(neat): 3112, 2983, 1666, 1592, 1573, 1469, 1431, 1316, 1133, 774

¹**H NMR** (400 MHz; CDCl₃) δ 12.0 (br s, 2H), 8.31 – 8.29 (m, 2H), 7.71 – 7.67 (m, 2H), 700– 6.94 (m, 4H), 3.42 (s, 6H); ¹³**C NMR** (101 MHz; CDCl₃) δ 156.8, 155.4, 146.3, 138.8, 117.5, 111.6, 33.1; HRMS m/z (ESI⁺) [C₁₄H₁₆N₆O₂Na] requires: 323.1232; found: 323.1228.

$$\begin{array}{c|c} O & Me \\ & N & N & N \\ & Me & O & N \end{array}$$

(*E*)-N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)diazene-1,2-dicarboxamide (1g); A solution of *N*-bromosuccinimide (396 mg, 2.23 mmol, 1.2 equiv) in DCM (12 mL, 0.15 M) was added dropwise to a solution of pyridine (0.34 mL, 4.2 mmol, 2 equiv) and N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)hydrazine-1,2-dicarboxamide **S1g** (560 mg, 1.8 mmol) in DCM (6 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3 × 20 mL). The combined organics were washed with brine (1 × 20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (40% EtOAc/Hexane) afforded the title compound (438 mg, 78%) as orange needles.

MP: 134-136 °C

*V*_{max} /cm⁻¹(neat): 2918, 1768, 1717, 1437, 1362, 1113, 785

¹**H NMR** (400 MHz, CDCl₃) δ 8.42 (d, J = 4.0 Hz, 2H), 7.73–7.69 (m, 2H), 7.26–7.25 (m, 2H), 7.17–7.14 (m, 2H), 3.35 (br s, 6H); ¹³**C NMR** (101 MHz, CDCl₃) δ 161.0, 152.9, 148.3, 137.9, 121.8, 119.6, 29.5; HRMS (ESI) calcd for [C₁₄H₁₄N₆O₂Na] requires [M + Na]+ 321.1076, found 321.1071

1.8 General Procedure 4: Carbamoyl Chloride and tert-Butyl carbamate coupling

Pyridine (2.0 equiv) was added in one portion to a solution of carbamoyl chloride and tert-butyl carbazate (1.3 equiv) in MeCN (0.5 M) and the resulting solution stirred at RT for 18-40 h. The reaction was quenched with H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO4 and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography.

1.9 General Procedure 5: Synthesis of unsymmetrical α , β unsaturated azocarbonamides

A solution of *N*-bromosuccinimide (1.2-1.5 equiv) in DCM (0.15 M) was added dropwise to a solution of pyridine (2 equiv) and arylcarbamoyl)hydrazine-1-carboxylate **S5** in DCM (11 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3×20 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography afforded the s an orange solid.

Me O H O H N N N N O O

tert-Butyl 2-(methyl(*p*-tolyl)carbamoyl)hydrazine-1-carboxylate (S5a). Pyridine (0.69 mL, 2 equiv) was added in one portion to a solution of methyl(*p*-tolyl)carbamic chloride (700 mg, 3.8 mmol, 1.0 equiv) and *tert*-butyl carbazate (656 mg, 4.9 mmol, 1.3 equiv) in MeCN (7.6 mL, 0.5 M) and the resulting solution stirred at RT for 18 h. The reaction was quenched with

H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (40% EtOAc/Petrol) afforded the title compound (1100 mg, 96%) as white needles.

M.P: 106-108 °C

*V*_{max} /cm⁻¹(neat): 3279, 2977, 1725, 1672, 1513, 1366, 1161, 1018, 754

¹**H** NMR (400 MHz; CDCl₃) δ 7.19 (d, J = 6.5 Hz, 4H), 6.32 (s, 1H), 6.03 (s, 1H), 3.23 (s, 3H), 2.34 (s, 3H), 1.41 (s, 9H); ¹³C NMR (101 MHz; CDCl₃) δ 157.2, 156.5, 139.5, 137.9, 130.8, 127.1, 81.2, 37.8, 28.3, 21.1; **HRMS m/z** (ESI⁺) [C₁₄H₂₁N₃O₃Na]⁺ requires[M + Na]⁺: 302.1481; found: 302.1493

Me O N N N O Me O

tert-Butyl (*E*)-2-(methyl(p-tolyl)carbamoyl)diazene-1-carboxylate (5a). A solution of *N*bromosuccinimide (952 mg, 4.5 mmol, 1.5 equiv) in DCM (22 mL, 0.15 M) was added dropwise to a solution of pyridine (0.651 mL, 7.1 mmol, 2 equiv) and tert-butyl 2-(methyl(*p*tolyl)carbamoyl)hydrazine-1-carboxylate **S4a** (1000 mg, 3.5 mmol) in DCM (11 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3×20 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (25% EtOAc/Hexane) afforded the title compound (860 mg, 87%) as an orange solid.

M.P: 83-85 °C


*V*_{max} /cm⁻¹(neat): 2982, 1762, 1710, 1513, 1371, 1254, 1150, 835

¹**H** NMR (400 MHz, CDCl₃) δ 7.13 (d, *J* = 8.1 Hz, 2H), 6.99 (d, *J* = 8.1 Hz, 2H), 3.47 (s, 3H), 2.32 (s, 3H), 1.48 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 161.0, 159.8, 138.0, 137.9, 130.0, 127.1, 86.2, 38.7, 27.8, 21.1; HRMS (ESI) calcd for $[C_{14}H_{19}N_3O_3Na]^+$ requires $[M + Na]^+$ 300.1324, found 300.1309.

tert-Butyl 2-(methyl(phenyl)carbamoyl)hydrazine-1-carboxylate (**S5b**). Pyridine (1.07 mL, 11.8 mmol, 2.0 equiv) was added in one portion to a solution of *N*-methyl-*N*-phenylcarbamoyl chloride (1 g, 5.9 mmol, 1.1 equiv) and *tert*-butyl carbazate (0.7 mg, 5.36 mmol, 1 equiv) in MeCN (25 mL, 0.21 M) and the resulting solution stirred at RT for 18 h. The reaction was quenched with H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (40% EtOAc/Petrol) afforded the *title compound* (1.1 g, 71%) as colourless oil.

*V*max /cm⁻¹(neat): 3287, 2977, 1690, 1494, 1157, 699


¹**H NMR** (400 MHz; CDCl₃) δ 7.47 – 7.40 (m, 2H), 7.38 – 7.29 (m, 3H), 6.42 (br s 1H), 6.11 (br s, 1H), 3.30 (s, 3H), 1.47 (s, 9H); ¹³**C NMR** (101 MHz; CDCl₃) δ 156.9, 156.4, 142.8, 130.2, 127.8, 127.2, 81.2, 37.7, 28.2; HRMS (ESI⁺) [C₁₃H₁₉N₃O₃Na^{]+} requires [M+Na]+: 288.1324; found: 288.1317



tert-Butyl (*E*)-2-(methyl(phenyl)carbamoyl)diazene-1-carboxylate (5b). A solution of *N*bromosuccinimide (540 mg, 3.05 mmol, 1.2 equiv) in DCM (16 mL, 0.15 M) was added dropwise to a solution of pyridine (0.46 mL, 6.12 mmol, 2 equiv) and tert-butyl (E)-2-(methyl(phenyl)carbamoyl)diazene-1-carboxylate **S5b** (674 mg, 2.5 mmol) in DCM (8 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 5 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3 × 20 mL). The combined organics were washed with brine (1 \times 20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAc/Hexane) afforded the *title compound* (357 mg, 53%) as an orange solid.

*V*_{max} /cm⁻¹(neat): 2982, 1762, 1711, 1598, 1371, 1255, 1149, 697

¹**H NMR** (400 MHz, CDCl₃) δ 7.40-7.36 (m, 2H), 7.32 (d, *J* = 8.0 Hz, 1H), 7.16 (d, *J* = 8.0 Hz, 2H), 3.55 (s, 3H) 1.51 (s, 9H); ¹³**C NMR** (100 MHz, CDCl₃) δ 160.8, 159.7, 140.5, 129.3, 127.9, 127.3, 86.2, 38.6, 27.7; HRMS (ESI) calcd for [C₁₃H₁₇N₃O₃Na] requires [M+ Na]+ 286.1168, found 286.1028




MP: 65-67 °C

tert-Butyl 2-((4-cyanophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5c). Pyridine (0.65mL, 2 equiv) was added in one portion to a solution of (4-cyanophenyl)(methyl)carbamic chloride (700 g, 3.6 mmol, 1.0 equiv) and *tert*-butyl carbazate (714 mg, 5.4 mmol, 1.5 equiv) in MeCN (7.2 mL, 0.5 M) and the resulting solution stirred at RT for 18 h. The reaction was quenched with H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (40% EtOAc/Petrol) afforded the title compound (1g, 95.6%) as a white solid.

MP: 161-163 °C

 V_{max} /cm⁻¹(neat): 3300, 2980, 2227, 1722, 1673, 1603, 1479, 1367, 1159, 1111, 847 ¹H NMR (400 MHz; CDCl₃) δ 7.72 – 7.67 (m, 2H), 7.50 (d, J = 7.8 Hz, 2H), 6.37 (s, 1H), 6.25 (s, 1H), 3.32 (s, 3H), 1.45 (s, 9H); ¹³C NMR (101 MHz; CDCl₃) δ 156.4, 146.8, 133.9, 126.9, 118.1, 110.5, 81.8, 37.4, 28.2; HRMS m/z (ESI⁺) [C₁₄H₁₈N₄O₃Na]⁺ requires[M + Na]⁺: 313.1277; found: 313.1283



tert-Butyl (*E*)-2-((4-cyanophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5c). A solution of *N*-bromosuccinimide (952 mg, 4.5 mmol, 1.5 equiv) in DCM (22 mL, 0.15 M) was added dropwise to a solution of pyridine (0.651 mL, 7.1 mmol, 2 equiv) and tert-butyl 2-((4-cyanophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate **S5c** (1040 mg, 3.5 mmol) in DCM (11 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3×20 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (25% EtOAc/Hexane) afforded the title compound (930 mg, 90%) as an orange solid. **MP:** 92-94 °C

 V_{max} /cm⁻¹(neat): 2984, 2230, 1760, 1709, 1603, 1253, 1147, 833 ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, J = 6.6 Hz, 2H), 7.30 – 7.20 (m, 2H), 3.52 (s, 3H), 1.52 (s, 9H); ¹³C NMR (126 MHz, CDCl₃) δ 159.6, 144.6, 133.2, 127.8, 117.9, 111.6, 86.9, 38.3, 27.7; HRMS (ESI) calcd for [C₁₄H₁₆N₄O₃Na]⁺ requires [M + Na]⁺ 311.1120, found 311.1118

tert-Butyl 2-((3-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5d). Pyridine (0.65mL, 2 equiv) was added in one portion to a solution of (3-chlorophenyl)(methyl)carbamic chloride (730 g, 3.6 mmol, 1.0 equiv) and *tert*-butyl carbazate (715 mg, 5.4 mmol, 1.5 equiv) in MeCN (7.2 mL, 0.5 M) and the resulting solution stirred at RT for 18 h. The reaction was quenched with H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (40% EtOAc/Petrol) afforded the title compound (1000 mg, 90%) as white needles.


*V*_{max} /cm⁻¹(neat): 3285, 2979, 1680, 1667, 1476, 1366, 1237, 1157, 696

¹H NMR (400 MHz; CDCl₃) δ 7.36 – 7.30 (m, 2H), 7.25 (s, 2H), 6.47 (s, 1H), 6.15 (s, 1H),
3.24 (s, 3H), 1.43 (s, 9H); ¹³C NMR (126 MHz; CDCl₃) δ 156.7, 156.4, 143.5, 135.5, 131.1,
128.0, 127.5, 125.4, 123.8, 81.5, 37.7, 28.4; HRMS m/z (ESI⁺) [C₁₃H₁₈ClN₃O₃Na]⁺ requires[M + Na]⁺: 322.0934; found: 322.0919

tert-Butyl (*E*)-2-((3-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5d). A solution of *N*-bromosuccinimide (799 mg, 4.5 mmol, 1.5 equiv) in DCM (20 mL, 0.15 M) was added dropwise to a solution of pyridine (0.546 mL, 6.0 mmol, 2 equiv) and tert-butyl 2-((3-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate S5d (900 mg, 3.01 mmol) in DCM (10 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3×20 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (15% EtOAc/Hexane) afforded the title compound (750 mg, 83%) as an orange semi-solid.

*V*_{max} /cm⁻¹(neat): 2983, 1761, 1709, 1591, 1370, 1251, 1147, 694

¹**H NMR** (400 MHz, CDCl₃) δ 7.28 (d, J = 5.5 Hz, 2H), 7.15 (s, 1H), 7.02 (d, J = 6.1 Hz, 1H), 3.50 (s, 3H), 1.50 (s, 9H); ¹³**C NMR** (101 MHz, CDCl₃) δ 160.5, 159.7, 141.7, 134.9, 130.3, 128.3, 127.6, 125.7, 86.6, 38.5, 27.8; HRMS (ESI) calcd for [C₁₃H₁₆ClN₃O₃Na]⁺ requires [M + Na]⁺ 320.0778, found 320.0777



tert-Butyl 2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)hydrazine-1-carboxylate (S5e). Pyridine (0.64 mL, 7.0 mmol, 2 equiv) was added in one portion to a solution of N-methyl(3-(trifluoromethyl)phenyl)carbamic chloride (840 g, 3.5 mmol, 1.0 equiv) and *tert*-

butyl carbazate (608 mg, 4.6 mmol, 1.3 equiv) in MeCN (7.0 mL, 0.5 M) and the resulting solution stirred at RT for 18 h. The reaction was quenched with H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% to 40% EtOAc/Petrol) afforded the title compound (1.1 g, 93%) as a white needle.

MP: 151-153 °C

*V*_{max} /cm⁻¹(neat): 3286, 2980, 1716, 1671, 1493, 1331, 1163, 1126, 1070

¹**H NMR** (400 MHz; CDCl₃) δ 7.47 – 7.40 (m, 4H), 6.29 (br s 1H), 6.03 (br s, 1H), 3.31 (s, 3H), 1.45 (s, 9H). ¹³**C NMR** (126 MHz; CDCl₃) δ 156.6, 156.3, 142.9, 132.6 (q, *J*_{C-F} =32.9 Hz), 130.8, 130.6, 124.4 (q, *J*_{C-F} =3.6 Hz), 123.9 (q, *J*_{C-F} =3.7 Hz), 123.7 (q, *J*_{C-F} = 272.2 Hz), 81.6, 37.8, 28.2; HRMS m/z (ESI⁺) [C₁₄H₁₈F₃N₃O₃Na]⁺ requires[M + Na]⁺: 356.1198; found: 356.1199

tert-Butyl (*E*)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate (5e). A solution of *N*-bromosuccinimide (877 mg, 4.95 mmol, 1.5 equiv) in DCM (22 mL, 0.15 M) was added dropwise to a solution of pyridine (0.599 mL, 6.59 mmol, 2 equiv) and *tert*-butyl 2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)hydrazine-1-carboxylate **S5e** (1.1g, 3.3 mmol) in DCM (11 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3 × 20 mL). The combined organics were washed with brine (1 × 20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAc/Hexane) afforded the title compound (874 mg, 80%) as an orange Semi-solid.

*V*_{max} /cm⁻¹(neat): 2986, 1764, 1713, 1371, 1329, 1253, 1123, 801, 700

¹**H NMR** (400 MHz, CDCl₃) δ 7.55 (d, *J* = 7.5 Hz, 1H), 7.49 (t, *J* = 7.8 Hz, 1H), 7.39 (s, 1H), 7.34 (d, *J* = 7.5 Hz, 1H), 3.54 (s, 3H), 1.47 (s, 9H); ¹³**C NMR** (100 MHz, CDCl₃) δ 160.2, 159.6, 141.2, 131.9 (q, *J*_{C-F} = 33.1 Hz), 130.5, 130.0, 125.8 (q, *J*_{C-F} = 272.6 Hz), 124.7 (q, *J*_{C-F} = 2.5 Hz), 124.3 (q, *J*_{C-F} = 2.8 Hz), 122.7 (q, *J*_{C-F} = 272.3 Hz), 86.6, 38.5, 27.6; HRMS (ESI) calcd for [C₁₄H₁₆F₃N₃O₃Na]⁺ requires [M + Na]⁺ 354.1041, found 354.1035

tert-Butyl 2-(methyl(pyridin-2-yl)carbamoyl)hydrazine-1-carboxylate (S5f). Pyridine (0.60 mL, 2 equiv) was added in one portion to a solution of *N*-methyl(pyridin-2-yl)carbamic chloride (568 g, 3.3 mmol, 1.0 equiv) and *tert*-butyl carbazate (573 mg, 4.3 mmol, 1.3 equiv) in MeCN (6.68 mL, 0.5 M) and the resulting solution stirred at RT for 18 h. The reaction was quenched with H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (50% EtOAc/Petrol) afforded the title compound (805 mg, 90%) as white needles.

MP: 155-157 °C

*V*_{max} /cm⁻¹(neat): 3273, 2977, 1731, 1690, 1477, 1436, 1162, 776


¹**H NMR** (400 MHz; CDCl₃) δ 11.58 (d, J = 2.5 Hz, 1H), 8.28–8.26 (m, 1H), 7.70 (dddd, J = 8.0, 7.4, 2.0, 0.6 Hz, 1H), 6.99 (m, 2H), 6.45 (d, J = 2.5 Hz, 1H), 3.40 (s, 3H), 1.47 (s, 9H); ¹³**C NMR** (126 MHz; CDCl₃) δ 157.5, 156.2, 155.2, 146.2, 138.9, 117.7, 111.7, 81.3, 33.2, 28.3; **HRMS m/z** (ESI⁺) [C₁₂H₁₈N₄O₃Na]⁺ requires[M + Na]⁺: 289.1277; found: 289.1272.

tert-Butyl (*E*)-2-(methyl(pyridin-2-yl)carbamoyl)diazene-1-carboxylate (5f). A solution of *N*-bromosuccinimide (788 mg, 4.46 mmol, 1.5 equiv) in DCM (19 mL, 0.15 M) was added dropwise to a solution of pyridine (0.539 mL, 5.93 mmol, 2 equiv) and *tert*-butyl 2-(methyl

(pyridin-2-yl)carbamoyl)hydrazine-1-carboxylate **S5f** (790 mg, 2.96 mmol) in DCM (9.5 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3×20 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAc/Hexane) afforded the title compound (588 mg, 75%) as an orange oil.

*V*_{max} /cm⁻¹(neat): 2982, 1760, 1708, 1587, 1470, 1437, 1369, 1252, 1146, 1110, 784

¹**H NMR** (400 MHz, CDCl₃) δ 8.47 – 8.43 (m, 1H), 7.71 (t, *J* = 7.6 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.17 (ddd, *J* = 7.5, 4.9, 0.9 Hz, 1H), 3.57 (s, 3H), 1.58 (s, 9H); ¹³**C NMR** (126 MHz, CDCl₃) δ 160.4, 159.8, 152.9, 148.5, 148.1, 137.8, 121.8, 86.6, 35.8, 27.7; HRMS (ESI) calcd for [C₁₂H₁₆N₄O₃Na]⁺ requires [M + Na]⁺ 287.1120, found 287.1116.



tert-Butyl 2-((3-methoxyphenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5g). Pyridine (0.67 mL, 2 equiv) was added in one portion to a solution of (3-methoxyphenyl)(methyl)carbamic chloride (736 g, 3.6 mmol, 1.0 equiv) and *tert*-butyl carbazate (634 mg, 4.8 mmol, 1.3 equiv) in MeCN (7.3 mL, 0.5 M) and the resulting solution stirred at RT for 18 h. The reaction was quenched with H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (40% EtOAc/Petrol) afforded the title compound (1g, 91%) as a white semi-solid.

V_{max} /cm⁻¹(neat): 3288, 2977, 1690, 1673, 1598, 1487, 1366, 1231, 1157, 1042, 701
¹H NMR (400 MHz; CDCl₃) δ 7.29 (t, J = 8.2 Hz, 1H), 6.91 – 6.81 (m, 3H), 6.45 (s, 1H), 6.17 (s, 1H), 3.78 (s, 3H), 3.24 (s, 3H), 1.42 (s, 9H); ¹³C NMR (101 MHz; CDCl₃) δ 160.8, 157.0,


156.4, 143.3, 130.8, 119.2, 113.6, 112.8, 81.3, 55.5, 37.6, 28.2; **HRMS m/z** (ESI⁺) $[C_{14}H_{21}N_3O_3Na]^+$ requires $[M + Na]^+$: 318.1430; found: 318.1424

tert-butyl (*E*)-2-((3-methoxyphenyl)(methyl)carbamoyl)diazene-1-carboxylate (5g). A solution of *N*-bromosuccinimide (621 mg, 3.5 mmol, 1.5 equiv) in DCM (15.5 mL, 0.15 M) was added dropwise to a solution of pyridine (0.424 mL, 4.6 mmol, 2 equiv) and tert-butyl 2-((4-methoxyphenyl)(methyl)carbamoyl)hydrazine-1-carboxylate **S5g** (690 mg, 2.3 mmol) in DCM (7.75 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (15% EtOAc/Hexane) afforded the title compound (500 mg, 72%) as orange needles.

MP: 97-99 °C

*V*_{max} /cm⁻¹(neat): 2981, 1759, 1720, 1602, 1371, 1254, 1148, 698

¹**H NMR** (400 MHz, CDCl₃) δ 7.22 (d, *J* = 8.1 Hz, 1H), 6.81 (dd, *J* = 8.3, 2.2 Hz, 1H), 6.71 (d, *J* = 7.8 Hz, 1H), 6.63 (t, *J* = 2.0 Hz, 1H), 3.77 (s, 3H), 3.50 (s, 3H), 1.49 (s, 9H); ¹³**C NMR** (101 MHz, CDCl₃) δ 160.9, 160.2, 159.8, 141.5, 130.0, 119.4, 114.0, 112.9, 86.3, 55.4, 38.5, 27.7; HRMS (ESI) calcd for [C₁₄H₁₉N₃O₄Na]⁺ requires [M + Na]⁺ 316.1273, found 316.1279.




tert-Butyl 2-((4-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5h). Pyridine (0.62 mL, 2 equiv) was added in one portion to a solution of (4-chlorophenyl)(methyl)carbamic chloride (700 g, 3.4 mmol, 1.0 equiv) and *tert*-butyl carbazate (594 mg, 4.5 mmol, 1.5 equiv) in MeCN (6.9 mL, 0.5 M) and the resulting solution stirred at RT for 18 h. The reaction was quenched with H_2O (20 mL) and the aqueous layer was extracted with DCM (3 × 15 mL). The combined organics were washed with brine (1 × 15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (40% EtOAc/Petrol) afforded the title compound (995 mg, 96%) as white needles.

MP: 84-86 °C

*V*_{max} /cm⁻¹(neat): 3287, 2978, 1716, 1668, 1490, 1366, 1158, 1013

¹**H NMR** (400 MHz; CDCl₃) δ 7.39 (d, J = 2.2 Hz, 1H), 7.37 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.3 Hz, 2H), 6.37 (s, 1H), 6.05 (s, 1H), 3.24 (s, 3H), 1.43 (s, 9H); ¹³**C NMR** (101 MHz; CDCl₃) δ 156.8, 156.4, 140.7, 133.6, 130.4, 128.6, 81.5, 37.7, 28.2; HRMS m/z (ESI⁺) [C₁₃H₁₈ClN₃O₃Na]⁺ requires[M + Na]⁺: 322.0934; found: 322.0922



tert-Butyl (*E*)-2-((4-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5h). A solution of *N*-bromosuccinimide (976 mg, 5.51 mmol, 1.5 equiv) in DCM (24 mL, 0.15 M) was added dropwise to a solution of pyridine (0.668 mL, 7.3 mmol, 2 equiv) and tert-butyl 2-((4-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate **S5h** (1100 mg, 3.6 mmol) in DCM (12 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (40 mL) and the aqueous layer was extracted with DCM (3×20 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAc/Hexane) afforded the title compound (896 mg, 82%) as an orange Needles.

MP: 80-82 °C

*V*_{max} /cm⁻¹(neat): 2983, 1761, 1708, 1492, 1252, 1148, 834

¹H NMR (400 MHz, CDCl₃) δ 7.32 (d, J = 8.6 Hz, 2H), 7.07 (d, J = 8.6 Hz, 2H), 3.49 (s, 3H), 1.50 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 160.5, 159.7, 139.1, 133.9, 129.6, 128.7, 86.5, 38.6, 27.7; HRMS (ESI) calcd for [C₁₃H₁₆ClN₃O₃Na]⁺ requires [M + Na]⁺ 320.0778, found 320.0772

tert-Butyl 2-(ethyl(naphthalen-1-yl)carbamoyl)hydrazine-1-carboxylate (**S5i**); Pyridine (0.36 mL, 2 equiv) was added in one portion to a solution of ethyl(naphthalen-1-yl)carbamic chloride (470 g, 2.1 mmol, 1.0 equiv) and *tert*-butyl carbazate (346 mg, 2.6 mmol, 1.3 equiv) in MeCN (4.0 mL, 0.5 M) and the resulting solution stirred at RT for 42 h. The reaction was quenched with H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAc/Petrol) afforded the title compound (500, 75%) as a white semi-solid.


*V*_{max} /cm⁻¹(neat): 3289, 2976, 1720, 1671, 1480, 1366, 1158, 776

¹**H NMR** (400 MHz; CDCl₃) δ 7.90 (dt, J = 17.2, 9.0 Hz, 3H), 7.59 – 7.46 (m, 4H), 6.22 (s, 1H), 5.89 (s, 1H), 4.14 (dq, J = 14.2, 7.1 Hz, 1H), 3.49 (dq, J = 14.1, 7.1 Hz, 1H), 1.42 (s, 9H), 1.14 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (101 MHz; CDCl₃) δ 156.3, 136.1, 135.0, 130.8, 129.2, 128.5, 127.5, 127.3, 126.9, 126.0, 122.9, 81.2, 44.7, 28.2, 13.8; HRMS (ESI⁺) [C₁₈H₂₃N₃O₃Na]⁺ requires[M + Na]⁺: 352.1637; found: 352.1628.

tert-Butyl (E)-2-(ethyl(naphthalen-1-yl)carbamoyl)diazene-1-carboxylate (5i); A solution of N-bromosuccinimide (322 mg, 1.8 mmol, 1.5 equiv) in DCM (8.1 mL, 0.15 M) was added dropwise to a solution of pyridine (0.220 mL, 2.4 mmol, 2 equiv) and tert-butyl 2-

(ethyl(naphthalen-1-yl)carbamoyl)hydrazine-1-carboxylate **S5i** (400 mg, 1.2 mmol) in DCM (4 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×20 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (10% EtOAc/Hexane) afforded the title compound (264 mg, 66%) as an orange semi-solid. *V*_{max}/cm⁻¹(neat): 2936, 1761, 1709, 1372, 1268, 1254, 1150, 776

¹**H NMR** (400 MHz, CDCl₃) δ 7.85 (t, J = 9.2 Hz, 3H), 7.60 – 7.50 (m, 2H), 7.46 – 7.41 (m, 1H), 7.31 (d, J = 7.3 Hz, 1H), 4.32 (dq, J = 14.4, 7.2 Hz, 1H), 3.70 (dq, J = 14.3, 7.2 Hz, 1H), 1.30–1.26 (m, 12H); ¹³**C NMR** (101 MHz, CDCl3) δ 161.4, 159.5, 134.6, 134.5, 130.4, 129.4, 128.5, 127.7, 127.5, 126.7, 125.2, 122.7, 85.8, 45.8, 27.5, 13.1; HRMS (ESI) calcd for [C₁₈H₂₁N₃O₃Na]⁺ requires [M + Na]⁺ 350.1481, found 350.1491.



*tert-B*utyl 2-((2-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5j); Pyridine (0.31 mL, 2 equiv) was added in one portion to a solution of (2-chlorophenyl)(methyl)carbamic chloride (352 g, 1.7 mmol, 1.0 equiv) and *tert*-butyl carbazate (299 mg, 2.2 mmol, 1.3 equiv) in MeCN (3.4 mL, 0.5 M) and the resulting solution stirred at RT for 18 h. The reaction was quenched with H₂O (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (40% EtOAc/Petrol) afforded the title compound (500 mg, 95%) as white needles.

MP: 107-109 °C

*V*_{max} /cm⁻¹(neat): 3267, 2977, 1719, 1650, 1359, 1150, 770

¹**H NMR** (400 MHz; CDCl₃) δ 7.48 (dd, *J* = 7.5, 2.1 Hz, 1H), 7.43 (d, *J* = 6.4 Hz, 1H), 7.35 – 7.27 (m, 2H), 6.32 (s, 1H), 5.87 (s, 1H), 3.20 (s, 3H), 1.43 (s, 9H); ¹³**C NMR** (101 MHz; CDCl₃) δ 156.5, 156.3, 138.9, 133.6, 131.1, 130.4, 129.9, 128.7, 81.3, 36.4, 28.2; HRMS m/z (ESI⁺) [C₁₃H₁₈ClN₃O₃Na]⁺ requires[M + Na]⁺: 322.0934; found: 322.0944

N N²N O C

tert-Butyl (*E*)-2-((2-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5j); A solution of *N*-bromosuccinimide (532 mg, 3.0 mmol, 1.5 equiv) in DCM (13 mL, 0.15 M) was added dropwise to a solution of pyridine (0.364 mL, 4.0 mmol, 2 equiv) and tert-butyl 2-((2-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate **S5j** (600 mg, 2.0 mmol) in DCM (6.5 mL, 0.30 M) at 0 °C. The reaction was stirred at RT for 3 h, before being quenched with sat. aq. NaHCO₃ (20 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organics were washed with brine (1×15 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (10% EtOAc/Hexane) afforded the title compound (410 mg, 68%) as an orange oil.

*V*_{max} /cm⁻¹(neat): 2983, 1761, 1715, 1481, 1370, 1252, 1480

¹**H NMR** (400 MHz, CDCl₃) δ 7.42 (ddt, *J* = 5.2, 3.0, 1.1 Hz, 1H), 7.30 – 7.25 (m, 3H), 3.42 (s, 3H), 1.45 (s, 9H); ¹³**C NMR** (101 MHz, CDCl3) δ 160.4, 159.8, 137.9, 132.9, 130.4, 130.1, 130.0, 127.9, 86.3, 37.5, 27.7; **HRMS** (ESI) calcd for [C₁₃H₁₆ClN₃O₃Na]⁺ requires [M + Na]⁺ 320.0778, found 320.0779

1.10 General Procedure 6: Synthesis of Silyl enol ether²

OMe

отмs (1-methoxyprop-1-en-1-yl)oxy)trimethylsilane. (2a) The compound was prepared according to a reported procedure.² Under nitrogen, a 2.0 M n-BuLi solution in cyclohexane (25 mL, 50

² Z. Huang, Z. Liu, J. (S.) Zhou, J. Am. Chem. Soc., 2011, 133, 15882–15885

mmol) in an addition funnel was slowly added to a stirred solution of i-Pr₂NH (7.6 mL, 54.5 mmol) in dry THF (80 mL) at 0 °C over 20 min. The mixture was stirred at 0 °C for 30 minutes and then it was cooled to -78 °C in a cooling bath. A solution of methyl propionate (4g, 45 mmol) and TMSCl (6.9 mL, 54 mmol) in dry THF (40 mL) was added slowly over 1.5 hours from the addition funnel. After stirring at -78 °C for additional 30 minutes, the mixture was slowly warmed up to 25 o C and kept stirred for 18 hours. At the end of the reaction, most of THF was removed by distillation under one atmosphere of argon. The residue was diluted with 80 mL of pentane and the resulting suspension was filtered through a fritted funnel (medium porosity) with pentane washings, to remove LiCl. The filtrate was concentrated, and the crude product was purified by distillation under vacuum which afforded the desired silyl ketene acetal as colorless oil (3.5 g *E*:*Z* :: 8:1).

¹**H NMR** (400 MHz, CDCl₃) δ 3.66 (q, J = 8.0 Hz, 1H), 3.51 (s, 3H), 1.48 (d, J = 8.0 Hz, 3H), 0.21 (s, 9H) ¹³**C NMR** (100 MHz, CDCl₃) δ 154.0, 78.8, 54.8, 9.5, 0.18; HRMS (ESI) calcd for [C₇H₁₆O₂SiNa] requires [M + Na]+ 183.0817, found 183.0821

Ph 、

,OMe о́тмs

(1-Methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (2b); Under nitrogen, a 2.0 M n-BuLi solution in cyclohexane (25 mL, 50 mmol) in an addition funnel was slowly added to a stirred solution of i-Pr₂NH (7.6 mL, 54.5 mmol) in dry THF (80 mL) at 0 °C over 20 min. The mixture was stirred at 0 °C for 30 minutes and then it was cooled to -78 °C in a cooling bath. A solution of methyl propionate (7.3 g, 45 mmol) and TMSCl (6.9 mL, 54 mmol) in dry THF (40 mL) was added slowly over 1.5 hours from the addition funnel. After stirring at -78 °C for additional 30 minutes, the mixture was slowly warmed up to 25 °C and kept stirred for 18 hours. At the end of the reaction, most of THF was removed by distillation under one atmosphere of argon. The residue was diluted with 80 mL of pentane and the resulting suspension was filtered through a fritted funnel (medium porosity) with pentane washings, to

remove LiCl. The filtrate was concentrated, under reduced pressure to give silvl ketene acetal as colorless oil (10 g E:Z: 18:1), which was taken on without further purification.

*V*_{max} /cm⁻¹(neat): 2952, 1735, 1435, 1159, 750, 698

¹**H NMR** (400 MHz, CDCl₃) δ 7.28–7.22 (m, 4H), 7.19–7.15 (m, 1H), 3.90 (t, *J* = 8.0 Hz, 1H), 3.58 (s, 3H), 3.36 (d, *J* = 8.0 Hz, 2H), 0.27 (s, 9H); ¹³**C NMR** (100 MHz, CDCl₃) δ 154.3, 143.0, 128.3, 128.2, 125.6, 83.6, 54.7, 30.9, 0.09; HRMS (ESI) calcd for [C₁₃H₂₀O₂SiNa] requires [M + Na]+ 259.1130, found 259.1133.

(*E*)-((1-methoxypent-1-en-1-yl)oxy)trimethylsilane (2c); Under nitrogen, a 2.0 M n-BuLi solution in cyclohexane (25 mL, 50 mmol) in an addition funnel was slowly added to a stirred solution of i-Pr₂NH (7.6 mL, 54.5 mmol) in dry THF (80 mL) at 0 °C over 20 min. The mixture was stirred at 0 °C for 30 minutes and then it was cooled to -78 °C in a cooling bath. A solution of methyl pentanoate (5.2 g, 45 mmol) and TMSCl (7.3 mL, 54 mmol) in dry THF (40 mL) was added slowly over 1.5 hours from the addition funnel. After stirring at -78 °C for additional 30 minutes, the mixture was slowly warmed up to 25 °C and kept stirred for 18 hours. At the end of the reaction, most of THF was removed by distillation under one atmosphere of argon. The residue was diluted with 80 mL of pentane and the resulting suspension was filtered through a fritted funnel (medium porosity) with pentane washings, to remove LiCl. The filtrate was concentrated, under reduced pressure to give silyl ketene acetal as colorless oil (7.4 g, *E:Z* :: 19:1), which was taken on without further purification.

*V*_{max} /cm⁻¹(neat): 2958, 1709, 1549, 1395, 1259, 1057, 772

¹**H NMR** (400 MHz, CDCl₃) δ 3.64 (t, *J* = 7.3 Hz, 1H), 3.47 (s, 3H), 1.89 (q, *J* = 7.3 Hz, 2H), 1.31 – 1.24 (m, 2H), 0.85 (t, *J* = 7.4 Hz, 3H), 0.19 (s, 9H); ¹³**C NMR** (100 MHz, CDCl₃) δ 153.7, 85.1, 54.8, 26.6, 23.8, 13.6, -0.3; HRMS (ESI) calcd for [C₉H₂₀O₂SiNa] requires [M + Na]+ 211.1130, found 211.1135 MeO

methyl 4-(benzyloxy)butanoate (S2d); To a solution of 4-(benzyloxy)butanoic acid (5 g, 25.7 mmol) in methanol (0.1M) was added conc. HCl (cat.) and the solution heated at 60 °C for 8h. The solution was allowed to cool and concentrated under reduced pressure. The colourless oil was dissolved in dichloromethane (20 ml) and washed with water and brine solution and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure to provide the methyl 4-(benzyloxy)butanoate (5.89 g) as a colourless oil. V_{max} /cm⁻¹(neat): 2950, 2857, 1733, 1436, 1169, 1103, 1058, 735.


¹**H NMR** (400 MHz, CDCl₃) δ 7.27 – 7.20 (m, 4H), 7.20 – 7.15 (m, 1H), 4.39 (s, 2H), 3.55 (s, 3H), 3.41 (t, J = 6.2 Hz, 2H), 2.34 (t, J = 7.4 Hz, 2H), 1.84 (ddd, J = 13.6, 7.4, 6.2 Hz, 2H); ¹³**C NMR** (101 MHz, CDCl₃) δ 173.8, 138.4, 128.3, 127.5, 127.5, 72.8, 69.1, 51.4, 30.8, 25.1; HRMS (ESI) calcd for [C₁₂H₁₆O₃Na]⁺ requires [M + Na]⁺ 231.0997, found 231.0993

Ph_O____OTMS

(4-(benzyloxy)-1-methoxybut-1-en-1-yl)oxy)trimethylsilane (2d) Under nitrogen, 2.0 M n-BuLi solution in cyclohexane (19 mL, 38 mmol) in an addition funnel was slowly added to a stirred solution of i-Pr₂NH (5.7 mL, 40.85 mmol) in dry THF (60 mL) at 0 °C over 20 min. The mixture was stirred at 0 °C for 30 minutes and then it was cooled to -78 o C in a cooling bath. A solution of methyl pentanoate (5.89 g, 28 mmol) and TMSCl (5.12 mL, 37.8 mmol) in dry THF (30 mL) was added slowly over 1.5 hours from the addition funnel. After stirring at -78 °C for additional 30 minutes, the mixture was slowly warmed up to 25 °C and kept stirred for 24 hours. At the end of the reaction, most of THF was removed by distillation under one atmosphere of argon. The residue was diluted with 50 mL of pentane and the resulting suspension was filtered through a fritted funnel (medium porosity) with pentane washings, to remove LiCl. The filtrate was concentrated, under reduced pressure to give silyl ketene acetal as colorless oil (8.1 g, *E*:*Z* 10:1), which was taken on without further purification.

*V*_{max} /cm⁻¹(neat): 2955, 2853, 1697, 1252, 1081


¹**H NMR** (400 MHz, CDCl₃) δ 7.37 – 7.32 (m, 4H), 7.29 – 7.24 (m, 1H), 4.52 (s, 2H), 3.72 (t, J = 7.3 Hz, 1H), 3.52 (s, 3H), 3.44 (t, J = 7.0 Hz, 2H), 2.31 (q, J = 7.1 Hz, 2H), 0.25 (s, 9H). ¹³**C NMR** (100 MHz, CDCl₃) δ 154.5, 138.9, 128.3, 127.6, 127.4, 80.4, 72.7, 71.1, 54.6, 25.3, -0.18.; HRMS (ESI) calcd for [C₁₅H₂₄O₂SiNa] requires [M + Na]+ 303.1392, found 303.1382 **1.11 X-ray crystallography: X-ray studies of 4b:**



Bond precision:	C-C = 0.0020 A	
Wavelength	0.71073	
Cell:	a=22.4783(5)	α=90
	b=11.4618(2)	β=92.056(2)
	c=15.6035(4)	γ=90
Volume	4017.53(15)	
Space group	C 2/c	
Hall group	-C 2yc	
Moiety formula	C21 H24 N4 O3	
Sum formula	C21 H24 N4 O3	
Dx,g cm-3	1.258	
h,k,lmax	29,15,20	
Tmin,Tmax	0.970,0.977	
Tmin'	0.953	


Data completeness	0.998
Theta(max)	27.949
R(reflections)	0.0430(3669)
wR2(reflections)	0.1129(4827)

X-ray studies of 7b:




	•	
Bond precision:	C-C = 0.0018 A	
Wavelength	0.71073	
Cell:	a = 21.1353(4)	α=90
	b = 9.1587(2)	β=92.271(1)
	c = 16.9027(3)	γ=90
Volume	3269.32(11)	
Space group	P 21/c	
Hall group	-P 2ybc	
Moiety formula	C16 H21 N3 O4	
Sum formula	C16 H21 N3 O4	
Dx,g cm-3	1.298	
h,k,lmax	27,12,22	
Tmin,Tmax	0.964,0.976	
Tmin'	0.951	
Data completeness	0.998	
Theta(max)	27.952	
R(reflections)	0.0376(6284)	
wR2(reflections)	0.0932(7838)	


1.12 ReactIR studies



1.13 Procedures and Analytical data of hydantoin formation from symmetrical azodicarboxamides




Silyl enol ether 2 (1 equiv.,) was added dropwise to a mixture of symmetric azocarboxamide compound 1 (1 equiv) and AgOTf (10 mol %.) in THF (0.1 M) at -78 °C. The reaction was warmed to RT after 30 minutes and stirred at RT for 3 h. After TLC showed consumption of symmetric azocarboxamide compound 1, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 4 h. The reaction was quenched with sat. aq. NH₄Cl (15 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1×10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography desired compound.



*V*_{max} /cm⁻¹(neat): 2950, 1739, 1687, 1659


Methyl *N*-(methyl(phenyl)carbamoyl)-*N*-(3-methyl-3-phenylureido)alaninate (3) (Semi-solid), ¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.20 (m, 7H), 7.14 (t, *J* = 7.3 Hz, 1H), 6.91 (d, *J* = 7.6 Hz, 2H), 5.82 (s, 1H), 4.75 (s, 1H), 3.56 (s, 3H), 3.26 (s, 3H), 3.13 (s, 3H), 1.23 (d, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.1, 160.0, 155.6, 145.4, 142.0, 129.8, 129.6, 127.6, 126.9, 125.3, 124.2, 57.5, 52.1, 39.8, 37.5, 14.3; HRMS (ESI) calcd for [C₂₀H₂₄N₄O₄Na]+ requires [M + Na]+ 407.1690, found 407.1690.



3-(3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)-1-methyl-1-phenylurea (4a), Methoxy-1-trimethylsilyloxypropene (60 mg, 0.37 mmol,) was added dropwise to a mixture of (*E*)-2-benzoyl-N-methyl-N-phenyldiazene-1-carboxamide **1a** (101 mg, 0.37 mmol) and AgOTf (8.5 mg, 10 mol %.) in THF (3.4 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 30 minutes and stirred at RT for 3 h. After TLC showed consumption of (*E*)-2benzoyl-N-methyl-N-phenyldiazene-1-carboxamide **1a**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 4 h. The reaction was quenched with sat. aq. NH4Cl (15 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (60% EtOAC/Hexane) afforded the title compound (91 mg, 75%) as colourless semi-solid.

*V*max /cm⁻¹(neat): 3295, 1786, 1721, 1698

¹**H NMR** (400 MHz, CDCl₃) δ 7.42 – 7.35 (m, 2H), 7.35 – 7.27 (m, 6H), 7.27 – 7.23 (m, 2H), 5.99 (s, 1H), 3.30 (s, 3H), 3.10 (s, 3H), 1.91 (s, 3H);¹³**C NMR** (100 MHz, CDCl3) δ 173.6, 155.7, 141.8, 137.2, 130.3, 129.0, 128.7, 128.2, 127.1, 125.9, 68.7, 38.2, 25.3, 20.1; HRMS (ESI) calcd for [C₁₉H₂₀N₄O₃Na]+ requires [M + Na]+ 375.1428, found 375.1430.




3-(3,5-Dimethyl-2,4-dioxo-5-(p-tolyl)imidazolidin-1-yl)-1-methyl-1-(p-tolyl)urea (4b); 1-Methoxy-1-trimethylsilyloxypropene (74 mg, 0.46 mmol,) was added dropwise to a mixture of (E)-N¹,N²-dimethyl-N¹-phenyl-N²-(*p*-tolyl)diazene-1,2-dicarboxamide **1b** (150 mg, 0.46 mmol) and AgOTf (11.6 mg, 10 mol %.) in THF (4.6 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 30 minutes and stirred at RT for 3 h. After TLC showed consumption of (E)-N¹,N²-dimethyl-N¹-phenyl-N²-(*p*-tolyl)diazene-1,2-dicarboxamide **1b**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 4 h. The reaction was quenched with sat. aq. NH₄Cl (15 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (60% EtOAC/Hexane) afforded the title compound (140 mg, 80%) as colourless needles.

MP: 166-168°C

*V*_{max} /cm⁻¹(neat): 3298, 2942, 1783, 1717, 1690, 1513, 1457, 824, 753


¹**H NMR** (400 MHz, CDCl₃) δ 7.15 (s, 4H), 7.11 (s, 4H), 5.98 (br s, 1H) 3.25 (s, 3H), 3.07 (s, 3H), 2.33 (s, 3H), 2.29 (s, 3H), 1.87 (s, 3H); ¹³**C NMR** (100 MHz, CDCl₃) δ 173.9, 155.9, 139.2, 138.6, 138.3, 134.3, 130.9, 129.7, 126.9, 125.8, 68.5, 38.2, 25.2, 21.1, 21.0, 20.0; HRMS (ESI) calcd for [C₂₁H₂₄N₄O₃Na] requires [M + Na]+ 403.1746, found 403.1743.



1-(4-Cyanophenyl)-3-(5-(4-cyanophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1methylurea (4c); 1-Methoxy-1-trimethylsilyloxypropene (48 mg, 0.30 mmol,) was added dropwise to a mixture of (*E*)-N¹,N²-bis(4-cyanophenyl)-N¹,N²-dimethyldiazene-1,2dicarboxamide **1c** (104 mg, 0.30 mmol) and AgOTf (7.5 mg, 10 mol %.) in THF (3 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 30 minutes and stirred at RT for 3 h. After TLC showed consumption of (*E*)-N¹,N²-bis(4-cyanophenyl)-N¹,N²-dimethyldiazene-1,2dicarboxamide **1c**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 4 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (1% to 10% (10% MeOH in DCM)/DCM) afforded the title compound (95 mg, 79%) as a white semi-solid.

*V*_{max} /cm⁻¹(neat): 3299, 3018, 2218, 1786, 1719, 1688, 1505, 1338, 844, 748

¹**H NMR** (400 MHz, CDCl₃) δ 7.65–7.62 (m, 1H), 7.60–7.57 (m, 3H), 7.56–7.53 (m, 1H), 7.45–7.41 (m, 3H), 6.27 (br s, 1H), 2.94 (s, 3H), 3.04 (s, 3H), 1.83 (s, 3H); ¹³**C NMR** (100 MHz, CDCl₃) δ 172.1, 155.6, 155.2, 148.8, 145.2, 134.0, 133.6, 132.6, 127.2, 127.0, 126.5, 118.0, 117.7, 112.8, 111.3, 68.4, 38.0, 25.5, 20.3; HRMS (ESI) calcd for [C₂₁H₁₈N₆O₃Na] requires [M + Na]+ 425.1338, found 425.1334.




1-(4-Fluorophenyl)-3-(5-(4-fluorophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1methylurea (4d); 1-Methoxy-1-trimethylsilyloxypropene (48 mg, 0.30 mmol,) was added dropwise to a mixture of (*E*)-N¹,N²-bis(4-fluorophenyl)-N¹,N²-dimethyldiazene-1,2dicarboxamide **1d** (100 mg, 0.30 mmol) and AgOTf (7.5 mg, 10 mol %.) in THF (3.0 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 15 minutes, and stirred at RT for 3 h. After TLC showed consumption of (*E*)-N¹,N²-bis(4-fluorophenyl)-N¹,N²-dimethyldiazene-1,2dicarboxamide **1d**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 4 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (50% to 70% EtOAC + Hexane) afforded the *title compound* (44 mg, 38%) as colourless needles.

MP: 130-132 °C

*V*_{max} /cm⁻¹(neat): 3299, 2988, 1784, 1716, 1683, 1508, 1452, 1222, 840, 751

¹**H NMR** (400 MHz, CDCl₃) δ 7.29–7.22 (m, 4H), 7.09–7.05 (m, 2H), 7.01–6.97 (m, 2H), 5.94 (br s, 1H), 3.24 (s, 3H), 3.07 (s, 3H), 1.84 (s, 3H); ¹³**C NMR** (100 MHz, CDCl3) δ 173.5, 163.5 (d, *J*_{C-F} = 249.2 Hz), 162.3 (d, *J*_{C-F} = 249.2 Hz), 155.7, 155.6, 137.7 (d, *J*_{C-F} = 3.0 Hz), 133.0(d, *J*_{C-F} = 3.0 Hz), 129.2 (d, *J*_{C-F} = 9.0 Hz) 128.0 (d, *J*_{C-F} = 9.0 Hz), 117.4 (d, *J*_{C-F} = 23.2 Hz), 115.9 (d, *J*_{C-F} = 23.2 Hz), 68.2, 38.4, 25.3, 20.4; HRMS (ESI) calcd for [C₁₉H₁₈F₂N₄O₃Na] requires [M + Na]+ 411.1245, found 411.1256.




1-(3-Chlorophenyl)-3-(5-(3-chlorophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1-

methylurea (4e); 1-Methoxy-1-trimethylsilyloxypropene (45 mg, 0.28 mmol,) was added dropwise to a mixture of (*E*)-N¹,N²-bis(3-chlorophenyl)-N¹,N²-dimethyldiazene-1,2-dicarboxamide **1e** (95 mg, 0.26 mmol) and AgOTf (6.5 mg, 10 mol %.) in THF (2.6 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 30 minutes and stirred at RT for 4 h. After TLC showed consumption of (*E*)-N¹,N²-bis(3-chlorophenyl)-N¹,N²-dimethyldiazene-1,2-dicarboxamide **1e**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 5 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (60% EtOAC/Hexane) afforded the title compound (97 mg, 89%) as a pale-yellow oil.


*V*_{max} /cm⁻¹(neat): 3287, 2942, 1785, 1718, 1689, 1591, 1470, 748, 695

¹**H NMR** (400 MHz, CDCl₃) δ 7.30–7.29 (m, 2H), 7.27–7.25 (m, 2H), 7.21–7.19 (m, 2H), 7.16–7.13 (,. 2H), 6.10 (br s, 1H), 3.26 (s, 3H), 3.07 (s, 3H), 1.85 (s, 3H); ¹³**C NMR** (100 MHz, CDCl3) δ 173.02, 155.5, 155.4, 145.4, 143.0, 139.2, 135.8, 131.3, 130.3, 129.0, 128.6, 127.5, 126.4, 125.3, 124.3, 68.3, 38.2, 25.4, 20.1; **HRMS** (ESI) calcd for [C₁₉H₁₈Cl₂N₄O₃Na] requires [M + Na]+ 443.0654, found 443.0644.



3-(3,5-Dimethyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl)-1-methyl-1-(**3-(trifluoromethyl)phenyl)urea (4f)**; (1-methoxyprop-1-en-1-yl)oxy) trimethylsilane (33 mg, 0.20 mmol,) was added dropwise to a mixture of (E)-N¹,N²-dimethyl-N¹,N²-bis(3-(trifluoromethyl)phenyl)diazene-1,2-dicarboxamide **1f** (100 mg, 0.23 mmol) and AgOTf (5.8 mg, 10 mol %.) in THF (2.3 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 15 minutes, and stirred at RT for 3 h. After TLC showed consumption of (*E*)-N¹,N²-dimethyl-N¹,N²-dimethyl-N¹,N²-bis(3-(trifluoromethyl)phenyl)diazene-1,2-dicarboxamide **1f** the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 3 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (50% to 70% EtOAC + Hexane) afforded the *title compound* (85 mg, 75%) as a colourless oil. *V***max /cm⁻¹(neat)**; 3284, 2987, 1786, 1718, 1449, 1120, 735, 698

¹**H NMR** (400 MHz, CDCl₃) δ 7.57–7.50 (m, 7H), 7.48–7.44 (m, 1H), 6.17 (br s, 1H), 3.30 (s 3H), 3.08 (s, 3H), 1.89 (s, 3H); ¹³**C NMR** (100 MHz, CDCl₃) 172.9, 155.6, 155.4, 142.5, 138.4, 132.9, 132.6, 131.5, 131.2, 130.9, 130.4 (q, *J*_{C-F} = 2.2 Hz), 129.6 (q, *J*_{C-F} = 2.0 Hz), 129.60, 125.7 (q, *J*_{C-F} = 3.8 Hz), 124.8 (q, *J*_{C-F} = 3.7 Hz), 123.9 (q, *J*_{C-F} = 3.8 Hz), 122.8 (q, *J*_{C-F} = 3.9 Hz), 68.3, 25.4, 20.6; HRMS (ESI) calcd for [C₂₁H₁₈F₆N₄O₃Na] requires [M + Na]+ 511.1181, found 511.1150.




3-(3,5-Dimethyl-2,4-dioxo-5-(pyridin-2-yl)imidazolidin-1-yl)-1-methyl-1-(pyridin-2-yl)

urea (4g); 1-Methoxy-1-trimethylsilyloxypropene (59 mg, 0.36 mmol,) was added dropwise to a mixture of (*E*)-N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)diazene-1,2-dicarboxamide **1g** (100 mg, 0.33 mmol) and AgOTf (8.4 mg, 10 mol %.) in THF (3.3 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 30 minutes, and stirred at RT for 4 h. After TLC showed consumption of (*E*)-N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)diazene-1,2-dicarboxamide **1g**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 4 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO4 and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (10% MeOH/DCM)) afforded the *title compound* (87 mg, 73%) as white needles.

MP: 179-181 °C

*V*_{max} /cm⁻¹(neat): 3264, 1786, 1716, 1687, 1434, 742


¹H NMR (400 MHz, CDCl₃) δ 12.09 (br s, 1H), 8.62–8.60 (m, 1H), 8.08–8.06 (m, 1H), 7.74–7.65 (m, 2H), 7.56–7.53 (m, 1H), 7.28–7.34 (m, 1H), 6.97–6.90 (m, 2H), 3.38 (s, 3H), 3.07 (s, 3H), 1.93 (s, 3H);
¹³C NMR (100 MHz, CDCl3) δ 172.8, 156.8, 156.4, 155.8, 155.0, 149.2, 145.8, 139.0, 137.4, 123.5, 121.8, 117.8, 111.8, 70.4, 33.2, 25.3, 19.9; HRMS (ESI) calcd for [C₁₇H₁₈N₆O₃Na] requires [M + Na]+ 377.1338, found 377.1320.



3-(5-Benzyl-5-(3-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)-1-(3-chlorophenyl) -1-methylure (4h); (1-methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (58 mg, 0.24 mmol,) was added dropwise to a mixture of (*E*)-N¹,N²-bis(3-chlorophenyl)-N¹,N²dimethyldiazene-1,2-dicarboxamide **1e** (100 mg, 0.27 mmol) and AgOTf (6.9 mg, 10 mol %.) in THF (2.7 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 15 minutes, and stirred at RT for 3 h. After TLC showed consumption of (*E*)-N¹,N²-bis(3-chlorophenyl)-N¹,N²dimethyldiazene-1,2-dicarboxamide **1e**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 3 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (50% to 70% EtOAC + Hexane) afforded the title compound (85 mg, 62%) as a colourless oil.

*V*_{max} /cm⁻¹(neat): 3333, 2983, 1788, 1711, 1590, 1452, 733, 698

¹**H NMR** (400 MHz, CDCl₃) δ 7.82 (d, J = 2.0 Hz, 1H), 7.76–7.73 (m, 1H), 7.44–7.43 (m, 2H), 7.36–7.35 (m, 1H), 7.31–7.30 (m, 1H), 7.21–7.16 (m, 3H), 7.07–7.03 (m, 2H) 6.97 (d, J = 8.0 Hz, 2H), 5.85 (br s, 1H), 3.27 (d, J = 12.0 Hz, 1H), 3.24 (s, 3H), 3.14 (d, J = 12.0 Hz, 1H), 3.00 (s, 3H); ¹³**C NMR** (100 MHz, CDCl3) 172.1, 155.9, 155.4, 143.3, 138.03, 135.9, 134.7, 133.8, 131.5, 130.1, 129.2, 129.1, 128.7, 128.6, 128.2, 128.1, 127.3, 125.9, 125.3, 72.7, 41.3, 38.0, 25.0; HRMS (ESI) calcd for [C₂₅H₂₂Cl₂N₄O₃Na] requires [M + Na]+ 519.0967, found 519.0963.




3-(5-Benzyl-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl)-1-

methyl-1-(3-(trifluoromethyl)phenyl)urea (4i); (1-methoxy-3-phenylprop-1-en-1yl)oxy)trimethylsilane (49 mg, 0.20 mmol,) was added dropwise to a mixture of (*E*)-N¹,N²dimethyl-N¹,N²-bis(3-(trifluoromethyl)phenyl)diazene-1,2-dicarboxamide **1f** (100 mg, 0.23 mmol) and AgOTf (5.8 mg, 10 mol %) in THF (2.3 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes, and stirred at RT for 3 h. After TLC showed consumption of (*E*)-N¹,N²-dimethyl-N¹,N²-bis(3-(trifluoromethyl)phenyl)diazene-1,2-dicarboxamide **1f**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 20 minutes the reaction was warmed to -40 °C and stirred at -40 °C for 3 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (50% to 70% EtOAC + Hexane) afforded the *title compound* (107 mg, 82%) as a colourless oil.

*V*_{max} /cm⁻¹(neat): 3260, 1787, 1720, 1447, 1328, 1126, 748

¹**H NMR** (400 MHz, CDCl₃) δ 8.07 (d, *J* = 8.0 Hz, 2H), 7.72 (d, *J* = 8.4 Hz, 1H), 7.65–7.61 (m, 2H), 7.58–7.54 (m, 2H), 7.49 (d, *J* = 8.3 Hz, 1H), 7.17–7.13 (m, 1H), 7.01–6.97 (m, 2H), 6.65 (d, *J* = 7.2 Hz, 2H), 5.82 (s, 1H), 3.76 (d, *J* = 14.0 Hz, 1H), 3.26 (s, 3H), 3.16 (d, *J* = 14.0 Hz, 1H), 2.88 (s, 3H); ¹³**C NMR** (100 MHz, CDCl3) δ 172.0, 155.8, 155.4, 142.8, 137.1, 133.7, 131.2, 131.1 (q, *J*_{C-F} = 1.0 Hz), 130.7 (q, *J*_{C-F} = 1.3 Hz), 129.4, 129.2, 128.5, 128.2, 125.8 (q, *J*_{C-F} = 3.8 Hz), 125.1 (q, *J*_{C-F} = 3.7 Hz), 124.7 (q, *J*_{C-F} = 3.7 Hz), 123.9 (q, *J*_{C-F} = 4.0 Hz), 72.7, 41.5, 38.1, 25.1; HRMS (ESI) calcd for [C₂₇H₂₂F₆N₄O₃Na] requires [M + Na]+ 587.1494, found 587.1475.



3-(5-Benzyl-3-methyl-2,4-dioxo-5-(pyridin-2-yl)imidazolidin-1-yl)-1-methyl-1-(pyridin-


2-yl)urea (4j); (1-methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (71 mg, 0.30 mmol,) was added dropwise to a mixture of (E)-N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)diazene-1,2-dicarboxamide **1g** (100 mg, 0.33 mmol) and AgOTf (5.8 mg, 8.4 mol %) in THF (3.3 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes, and stirred at RT for 3 h. After TLC showed consumption of (E)-N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)diazene-1,2-dicarboxamide **1g**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -40 °C for 3 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (50% to 70% EtOAC + Hexane) afforded the *title compound* (95 mg, 65%) as a colourless semi-solid.

*V*_{max} /cm⁻¹(neat): 3234, 2989, 1787, 1718, 1690, 1593, 1434, 731, 699


¹**H NMR** (400 MHz, CDCl₃) δ 12.23 (s, 1H), 8.64 – 8.60 (m, 1H), 8.22 (dd, J = 5.2, 1.5 Hz, 1H), 7.75 – 7.72 (m, 2H), 7.40 (d, J = 7.0 Hz, 2H), 7.29 – 7.24 (m, 5H), 6.99 (dd, J = 7.3, 5.0 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 3.82 (d, J = 14.2 Hz, 1H), 3.70 (d, J = 14.2 Hz, 1H), 3.31 (s, 3H), 2.84 (s, 3H). ¹³**C NMR** (101 MHz, CDCl₃) δ 171.8, 156.4, 155.5, 155.0, 154.8, 149.0, 145.5, 139.2, 138.1, 137.0, 134.5 130.3, 127.5, 128.48, 123.7, 122.8, 117.9, 111.9, 74.6, 38.4, 33.3, 24.9; HRMS (ESI) calcd for [C₂₃H₂₂N₆O₃Na] requires [M + Na]⁺ 453.1651, found 453.1647.

1.13General Procedure 7: A general, connective synthesis of protected N-

aminohydantoins (7):




Silyl enol ether **2** (1 equiv,) was added dropwise to a mixture of azocarboxylate **5** (1 equiv) and AgOTf (10 mol %) in THF (0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2-3 h. After TLC showed consumption of azocarboxylate **5**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 1-4 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc $(3 \times 10 \text{ mL})$. The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (EtOAC + Hexane) afforded the title compound.



tert-Butyl2-(1-methoxy-1-oxopropan-2-yl)-2-(methyl(p-tolyl)carbamoyl)hydrazinecarboxylate (6) ¹H NMR (400 MHz, CDCl₃) δ 7.17 – 7.02 (m, 4H), 5.93 (br s, 1H),4.86 (br s, 1H), 3.69 (s, 3H), 3.19 (s, 3H), 2.30 (s, 3H), 1.44 – 1.24 (m, 12H); ¹³C NMR (101MHz, CDCl₃) δ 171.2, 159.9, 154.4, 142.3, 135.7, 130.1, 124.7, 80.6, 66.8, 52.2, 40.1, 28.1,20.9, 14.1. HRMS (ESI) calcd for [C18H27N3O5Na] requires [M + Na]+ 388.1848, found388.1845.

1.15 Procedure and Analytical data of aza boc-hydantoins (7)




tert-Butyl (3,5-dimethyl-2,4-dioxo-5-(p-tolyl)imidazolidin-1-yl)carbamate (7a); (1methoxyprop-1-en-1-yl)oxy)trimethylsilane (66 mg, 0.41 mmol,) was added dropwise to a mixture of tert-butyl (*E*)-2-(methyl(*p*-tolyl)carbamoyl)diazene-1-carboxylate **4a** (115 mg, 0.41 mmol) and AgOTf (10.4 mg, 10 mol %) in THF (4.1 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2 h. After TLC showed consumption of **4a**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO4 and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAC + Hexane) afforded the title compound (100 mg, 72%) as a colourless needle

MP: 180-182 °C

*V*_{max} /cm⁻¹(neat): 3289, 2979, 1786, 1710, 1454, 1245, 1157, 1046, 756

¹**H NMR** (400 MHz, CDCl₃) δ 7.23 – 7.14 (m, 4H), 6.56 (s, 1H), 3.09 (s, 3H), 2.33 (s, 3H), 1.83 (s, 3H), 1.44 (s, 9H); ¹³**C NMR** (126 MHz, CDCl₃) δ 173.6, 155.3, 154.7, 138.8, 133.6, 129.8, 125.9, 82.5, 68.3, 28.0, 25.2, 21.0, 19.9; HRMS (ESI) calcd for [C₁₇H₂₃N₃O₄Na]⁺ requires [M + Na]⁺ 356.1586, found 356.1587




tert-Butyl (3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)carbamate (7b); 1-Methoxy-1-trimethylsilyloxypropene (71 mg, 0.44 mmol,) was added dropwise to a mixture of tert-butyl (*E*)-2-(methyl(phenyl)carbamoyl)diazene-1-carboxylate **5b** (100 mg, 0.38 mmol) and AgOTf (9.5 mg, 10 mol %.) in THF (3.8 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 30 minutes and stirred at RT for 2 h. After TLC showed consumption of **5b**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAC/Hexane) afforded the title compound (78 mg, 60%) as white needles.

MP: 176-178 °C

*V*max /cm⁻¹(neat): 3289, 2980, 1787, 1707, 1448, 1155, 751

¹**H NMR** (400 MHz, CDCl₃) δ 7.40–7.31 (m, 5H), 6.33 (br s, 1H), 3.09 (s, 3H), 1.85 (s, 3H), 1.43 (s, 9H); ¹³**C NMR** (100 MHz, CDCl3) δ 173.4, 154.6, 129.1, 128.9, 125.9, 82.6, 68.5, 28.0, 25.2, 19.9; HRMS (ESI) calcd for [C₁₆H₂₁N₃O₄Na] requires [M + Na]+ 342.1430, found 342.1419.




tert-Butyl (5-(4-cyanophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)carbamate (7c); (1-methoxyprop-1-en-1-yl)oxy)trimethylsilane (77 mg, 0.48 mmol,) was added dropwise to a mixture of tert-butyl (E)-2-((4-cyanophenyl)(methyl)carbamoyl)diazene-1-carboxylate **5c** (140 mg, 0.48 mmol) and AgOTf (12.2 mg, 10 mol %) in THF (4.8 mL, 0.1 M) at -78 °C. The

reaction was warmed to RT after 10 minutes and stirred at RT for 3 h. After TLC showed consumption of tert-butyl (*E*)-2-((4-cyanophenyl)(methyl)carbamoyl)diazene-1-carboxylate **5c**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc $(3 \times 10 \text{ mL})$. The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAC + Hexane) afforded the title compound (120 mg, 71.8%) as a colourless needle

MP: 180-182 °C

 V_{max} /cm⁻¹(neat): 3298, 2981, 2230, 1789, 1712, 1454, 1246, 1156, 1047, 845, 753 ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, J = 8.7 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 6.35 (s, 1H), 3.10 (s, 3H), 1.87 (s, 3H), 1.44 (s, 9H); ¹³C NMR (126 MHz, CDCl₃) δ 172.3, 155.1, 154.6, 142.0, 132.6, 127.0, 118.1, 112.8, 83.0, 68.2, 28.0, 25.4, 20.3; HRMS (ESI) calcd for [C₁₇H₂₀N₄O₄Na]⁺ requires [M + Na]⁺ 367.1382, found 367.1388.




tert-Butyl (5-(3-chlorophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)carbamate (7d); (1-methoxyprop-1-en-1-yl)oxy)trimethylsilane (67 mg, 0.41 mmol,) was added dropwise to a mixture of tert-butyl (E)-2-((3-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate **5d** (125 mg, 0.42 mmol) and AgOTf (10.6 mg, 10 mol %) in THF (4.2 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2 h. After TLC showed consumption of tert-butyl (E)-2-((3-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate **5d**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction

was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc $(3 \times 10 \text{ mL})$. The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (25% EtOAC+Hexane) afforded the title compound (90 mg, 60%) as a colourless needle

MP: 169-171 °C

*V*_{max} /**cm**⁻¹(**neat**): 3293, 2979, 1788, 1708, 1453, 1244, 1155, 1046, 753 ¹H NMR (400 MHz, CDCl₃) δ 7.32 (d, *J* = 3.0 Hz, 3H), 7.23 (dd, *J* = 4.2, 2.9 Hz, 1H), 6.37 (s, 1H), 3.10 (s, 3H), 1.84 (s, 3H), 1.44 (s, 9H); ¹³C NMR (126 MHz, CDCl3) δ 172.8, 155.0, 154.6, 135.1, 130.3, 129.1, 126.4, 124.3, 82.8, 68.1, 28.0, 25.4, 20.1.HRMS (ESI) calcd for [C₁₆H₂₀ClN₃O₄Na]⁺ requires [M + Na]⁺ 376.1040, found 376.1041



tert-Butyl

(3,5-dimethyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-


yl)carbamate (7e); (1-methoxyprop-1-en-1-yl)oxy)trimethylsilane (48 mg, 0.30 mmol,) was added dropwise to mixture of tert-butyl (E)-2-(methyl(3а (trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate 5e (100 mg, 0.30 mmol) and AgOTf (7.6 mg, 10 mol %) in THF (3.0 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes, and stirred at RT for 3 h. After TLC showed consumption of tert-butyl (E)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate 5e, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica

chromatography (30% EtOAC + Hexane) afforded the *title compound* (91 mg, 65%) as colourless needles.

MP: 177-179 °C


*V*_{max} /cm⁻¹(neat): 3292, 2982, 1789, 1709, 1328, 1123, 754, 699

¹**H NMR** (400 MHz, CDCl₃) δ 7.66 – 7.54 (m, 3H), 7.54 – 7.46 (m, 1H), 6.64 (s, 1H), 3.09 (s, 3H), 1.87 (s, 3H), 1.41 (s, 9H); ¹³**C NMR** (100 MHz, CDCl₃) δ 172.8, 155.4, 154.8, 138.1, 131.6, 131.3, 130.9, 127.7 (q, *J*_{C-F} = 2.6 Hz), 129.6, 126.2 (q, *J*_{C-F} = 272.2 Hz), 125.7 (q, *J*_{C-F} = 3.6 Hz), 122.9 (q, *J*_{C-F} = 3.5 Hz), 82.9, 68.3, 28.0, 25.4, 20.5; HRMS (ESI) calcd for [C₁₇H₂₀F₃N₃O₄Na]⁺ requires [M + Na]⁺ 410.1304, found 410.1283



tert-Butyl (3,5-dimethyl-2,4-dioxo-5-(pyridin-2-yl)imidazolidin-1-yl)carbamate (7f); (*E*)-((1-methoxyprop-1-en-1-yl)oxy)trimethylsilane (60 mg, 0.37 mmol,) was added dropwise to a mixture of *tert*-butyl (E)-2-(methyl(pyridin-2-yl)carbamoyl)diazene-1-carboxylate **5f** (100 mg, 0.37 mmol) and AgOTf (9.5 mg, 8.4 mol %) in THF (3.7 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes, and stirred at RT for 3 h. After TLC showed consumption of *tert*-butyl (E)-2-(methyl(pyridin-2-yl)carbamoyl)diazene-1-carboxylate **5f**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -40 °C for 2 h. The reaction was quenched with sat. aq. NH4Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAC + Hexane) afforded the *title compound* (60 mg, 50%) as a colourless semi-solid. *V*_{max} /cm⁻¹(neat): 3288, 2980, 1789, 1711, 1452, 1154, 748


¹**H NMR** (400 MHz, CDCl₃) δ 8.46 (ddd, J = 4.8, 1.7, 0.8 Hz, 1H), 7.69 (td, J = 7.8, 1.8 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.23 – 7.18 (m, 1H), 6.83 (s, 1H), 2.99 (s, 3H), 1.83 (s, 3H), 1.40 (s, 9H); ¹³**C NMR** (100 MHz, CDCl₃) δ 172.3, 154.7, 149.2, 137.5, 123.5, 121.6, 81.9, 69.9, 28.1, 25.2, 19.8; HRMS (ESI) calcd for [C₁₅H₂₀N₄O₄Na]⁺ requires [M + Na]⁺ 343.1382, found 343.1370



tert-Butyl (5-benzyl-3-methyl-2,4-dioxo-5-(*p*-tolyl)imidazolidin-1-yl)carbamate (7g); (1methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (85 mg, 0.36 mmol,) was added dropwise to a mixture of tert-butyl (*E*)-2-(methyl(p-tolyl)carbamoyl)diazene-1-carboxylate **5a** (100 mg, 0.36 mmol) and AgOTf (9.0 mg, 10 mol %) in THF (3.6 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2 h. After TLC showed consumption of tert-butyl (*E*)-2-(methyl(p-tolyl)carbamoyl)diazene-1-carboxylate **5a**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH4Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO4 and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAC + Hexane) afforded the title compound (125 mg, 85%) as a semi-solid.

*V*_{max} /cm⁻¹(neat): 2978, 1730, 1665, 1513, 1366, 1238, 1153, 749

¹**H NMR** (400 MHz, CDCl₃) δ 7.26 – 7.17 (m, 4H), 7.09 (dt, *J* = 12.0, 6.0 Hz, 5H), 3.20 (s, 3H), 3.08 (dd, *J* = 13.8, 6.0 Hz, 1H), 3.02 – 2.89 (m, 1H), 2.32 (s, 3H), 1.39 (s, 9H); ¹³**C NMR** (101MHz, CDCl₃) δ 171.2, 160.0, 154.4, 142.1, 137.5, 135.6, 130.1, 129.2, 128.2, 126.4, 124.4, 81.0, 61.0, 39.9, 35.3, 28.1, 20.9; HRMS (ESI) calcd for [C₂₃H₂₇N₃O₄Na]⁺ requires [M + Na]⁺ 432.1899, found 432.1902




(5-benzyl-5-(3-methoxyphenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl) tert-Butyl carbamate (7h); (1-methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (80 mg, 0.34 mmol,) was added dropwise to mixture of tert-butyl (E)-2-((3a methoxyphenyl)(methyl)carbamoyl)diazene-1-carboxylate 5g (100 mg, 0.34 mmol) and AgOTf (8.6 mg, 10 mol %) in THF (3.4 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 3.5 h. After TLC showed consumption of tert-butyl (E)-2-((3-methoxyphenyl)(methyl)carbamoyl)diazene-1-carboxylate 5g, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (25% EtOAC + Hexane) afforded the title compound (75 mg, 51%) as colorless semi-solid

*V*_{max} /cm⁻¹(neat): 3282, 2978, 1788, 1709, 1453, 1155, 734, 700

¹**H NMR** (400 MHz, CDCl₃) δ 7.35 – 7.26 (m, 4H), 7.18 (dd, *J* = 7.6, 1.7 Hz, 3H), 7.13 (d, *J* = 7.7 Hz, 1H), 6.91 (dd, *J* = 8.2, 2.4 Hz, 1H), 6.35 (s, 1H), 3.80 (s, 3H), 3.63 – 3.48 (m, 2H), 2.81 (s, 3H), 1.32 (s, 9H); ¹³**C NMR** (101MHz, CDCl₃) δ 172.2, 159.8, 154.9, 154.5, 136.7,

134.0, 129.8, 129.6, 128.9, 127.9, 119.5, 82.5, 72.9, 55.4, 40.3, 27.8, 24.8; HRMS (ESI) calcd for $[C_{23}H_{27}N_3O_5Na]^+$ requires $[M + Na]^+$ 448.1848, found 448.1844




tert-Butyl (5-benzyl-5-(4-cyanophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate (7i); (*E*)-((1-methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (73 mg, 0.30 mmol,) was added dropwise to a mixture of tert-butyl (E)-2-((4-cyanophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5c (100 mg, 034 mmol) and AgOTf (8.7 mg, 10 mol %) in THF (3.4 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 1 h. After TLC showed consumption of tert-butyl (*E*)-2-((4-cyanophenyl) (methyl)carbamoyl)diazene-1-carboxylate 5c, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 1 h. The reaction was quenched with sat. aq. NH4Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1×10 mL), dried over MgSO4 and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAC + Hexane) afforded the title compound (120 mg, 82%) as colourless needles

MP: 184-185 °C

*V*_{max} /cm⁻¹(neat): 3295, 2980, 2231, 1790, 1712, 1454, 1156, 754

¹**H NMR** (500 MHz, CDCl₃) δ 7.82 (d, J = 7.8 Hz, 2H), 7.73 (d, J = 8.7 Hz, 2H), 7.39 – 7.31 (m, 3H), 7.17 (dd, J = 7.6, 1.7 Hz, 2H), 6.24 (s, 1H), 3.67 (d, J = 12.9 Hz, 1H), 3.49 (d, J = 13.9 Hz, 1H), 2.88 (s, 3H), 1.39 (s, 9H); ¹³**C NMR** (126 MHz, CDCl3) δ 171.4, 154.7, 154.3, 140.4, 133.2, 132.3, 129.3, 129.1, 128.3, 128.2, 118.3, 112.9, 83.1, 72.5, 40.3, 27.8, 24.9; HRMS (ESI) calcd for [C₂₃H₂₄N₄O₄Na]⁺ requires [M + Na]⁺ 443.1695, found 443.1672




tert-Butyl (5-benzyl-5-(4-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate (7j); (1-methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (79 mg, 0.33 mmol,) was added dropwise to a mixture of tert-butyl (*E*)-2-((4-chlorophenyl)(methyl)carbamoyl) diazene-1-carboxylate **5h** (100 mg, 0.33 mmol) and AgOTf (8.4 mg, 10 mol %) in THF (3.3 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2 h. After TLC showed consumption of tert-butyl (*E*)-2-((4-chlorophenyl)(methyl)carbamoyl) diazene-1-carboxylate **5h**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1×10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAC + Hexane) afforded the title compound (120 mg, 83%) as a white needls.

MP: 169-171°C

*V*_{max} /cm⁻¹(neat): 3273, 2979, 1789, 1708, 1453, 1156, 753


¹**H NMR** (400 MHz, CDCl₃) δ 7.53 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 8.7 Hz, 2H), 7.29 (q, J = 5.5 Hz, 3H), 7.14 (dd, J = 7.5, 1.8 Hz, 2H), 6.25 (s, 1H), 3.61 – 3.42 (m, 2H), 2.82 (s, 3H), 1.33 (s, 9H); ¹³**C NMR** (101MHz, CDCl3) δ 171.9, 154.6, 154.4, 135.0, 133.7, 133.6, 129.5, 128.9, 128.8, 128.7, 127.9, 82.7, 72.3, 40.2, 27.8, 24.7; HRMS (ESI) calcd for [C₂₂H₂₄ClN₃O₄Na]⁺ requires [M + Na]⁺ 452.1353, found 452.1338



tert-Butyl (5-benzyl-5-(3-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate (7k); (1-methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (76 mg, 0.32 mmol,) was added dropwise to a mixture of tert-butyl (E)-2-((3-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5d (107 mg, 0.36 mmol) and AgOTf (9.07 mg, 10 mol %) in THF (3.6 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2 h. After TLC showed consumption of tert-butyl (*E*)-2-((3-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5d, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1×10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAC + Hexane) afforded the title compound (113 mg, 78%) as a colourless needle MP: 152-154 °C.

*V*_{max} /cm⁻¹(neat): 3268, 2980, 1789, 1709, 1454, 1155, 753, 701

¹**H NMR** (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8.3 Hz, 2H), 7.70 (d, *J* = 8.4 Hz, 2H), 7.32 (qd, *J* = 5.9, 2.2 Hz, 3H), 7.13 (dd, *J* = 7.5, 1.9 Hz, 2H), 6.19 (s, 1H), 3.63 (d, *J* = 14.3 Hz, 1H), 3.45 (d, *J* = 13.9 Hz, 1H), 2.84 (s, 3H), 1.35 (s, 9H); ¹³**C NMR** (101MHz, CDCl3) δ 171.7, 155.0, 154.5, 137.2, 134.6, 133.5, 130.0, 129.7, 129.1, 128.8, 128.0, 127.7, 125.7, 82.7, 72.4, 40.2, 27.8, 24.8; HRMS (ESI) calcd for [C₂₂H₂₄ClN₃O₄Na]⁺ requires [M + Na]⁺ 452.1353, found 452.1331




tert-Butyl (5-benzyl-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-

vl)carbamate (7l); (1-methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (121.9 mg, 0.51 mmol,) was added dropwise to а mixture of tert-butyl (E)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate 5e (190 mg, 0.57 mmol) and AgOTf (15.2 mg, 10 mol %) in THF (6.0 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes, and stirred at RT for 3 h. After TLC showed consumption of tert-butyl (E)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate 5e, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -40 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAC + Hexane) afforded the title compound (155 mg, 70%) as colourless needles.

MP: 141-143 °C

*V*_{max} /cm⁻¹(neat): 3268, 2988, 1790, 1713, 1329, 1129, 748, 699

¹**H NMR** (400 MHz, CDCl₃) δ 7.78 (s, 1H), 7.65 (d, *J* = 7.9 Hz, 1H), 7.50 (d, *J* = 7.7 Hz, 1H), 7.40 (t, *J* = 7.9 Hz, 1H), 7.16 (d, *J* = 7.1 Hz, 3H), 7.02 (dd, *J* = 7.5, 1.9 Hz, 2H), 6.26 (s, 1H), 3.41 (dd, *J* = 16.9, 13.6 Hz, 2H), 2.69 (s, 3H), 1.16 (s, 9H); ¹³**C NMR** (100 MHz, CDCl3) δ 171.6, 154.6, 154.2, 136.4, 133.4, 130.9 (q, *J*_{C-F} = 12.4 Hz), 129.4, 129.2, 128.9, 128.1, 125.7 (q, *J*_{C-F} = 3.8 Hz), 125.2 (q, *J*_{C-F} = 272.5 Hz), 124.0 (q, *J*_{C-F} = 3.8 Hz), 82.8, 72.4, 40.6, 27.7, 24.8; HRMS (ESI) calcd for [C₂₃H₂₄F₃N₃O₄Na]⁺ requires [M + Na]⁺ 486.1617, found 486.1615



tert-Butyl (5-benzyl-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl) carbamate (7m); (1-methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (126 mg, 0.53 mmol,) was added dropwise to a mixture of tert-butyl (*E*)-2-(methyl(pyridin-2-yl)carbamoyl)diazene-1-carboxylate **5f** (157 mg, 0.59 mmol) and AgOTf (14.9 mg, 10 mol %) in THF (5.94 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes, and stirred at RT for 2 h. After TLC showed consumption of tert-butyl (*E*)-2-(methyl(pyridin-2-yl)carbamoyl)diazene-1-carboxylate **5f**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1×10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% EtOAC + Hexane) afforded the title compound (163 mg, 85%) as a pale-yellow semi-solid.

*V*_{max} /cm⁻¹(neat): 2977, 1792, 1706, 1594, 1435, 1136, 748


¹H NMR (400 MHz, CDCl₃) δ 11.77 (s, 1H), 8.26 (d, *J* = 3.6 Hz, 1H), 7.77 – 7.65 (m, 1H),
7.31 (d, *J* = 7.1 Hz, 2H), 7.28 – 7.23 (m, 2H), 7.18 (t, *J* = 7.0 Hz, 1H), 6.99 (d, *J* = 8.5 Hz,
2H), 3.40 (s, 3H), 3.25 (dd, *J* = 13.4, 7.9 Hz, 1H), 3.14 (dd, *J* = 14.0, 7.5 Hz, 1H), 1.37 (s,
9H); ¹³C NMR (101 MHz, CDCl3) 171.2, 157.4, 155.3, 146.0, 138.9, 138.0, 137.2, 129.4,
128.5, 128.3, 126.4, 117.6, 111.8, 82.07 74.14, 33.39, 28.08, 14.15; HRMS (ESI) calcd for
[C₂₁H₂₄N₄O₄Na]⁺ requires [M + Na]⁺ 419.1695, found 419.1675

tert-Butyl (5-benzyl-3-methyl-5-(naphthalen-1-yl)-2,4-dioxoimidazolidin-1-yl)carbamate (7n); (1-methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (81 mg, 0.34 mmol,) was added

dropwise to a mixture of tert-butyl (E)-2-(ethyl(naphthalen-1-yl)carbamoyl)diazene-1carboxylate **5i** (100 mg, 0.34 mmol) and AgOTf (8.7 mg, 10 mol %) in THF (3.4 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2.5 h. After TLC showed consumption of tert-butyl (E)-2-(ethyl(naphthalen-1-yl)carbamoyl)diazene-1carboxylate **5i**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 4 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1×10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAC + Hexane) afforded the title compound (90 mg, 56%) as colorless oil.

*V*_{max} /cm⁻¹(neat): 3264, 2978, 1785, 1712, 1495, 1392, 1158, 775

¹**H NMR** (400 MHz, CDCl₃) δ 7.88 – 7.78 (m, 3H), 7.53 – 7.42 (m, 3H), 7.39 – 7.30 (m, 3H), 7.28 – 7.21 (m, 3H), 6.21 (s, 1H), 4.00 (d, *J* = 13.0 Hz, 1H), 3.54 (d, *J* = 12.9 Hz, 1H), 3.25 (q, *J* = 7.2 Hz, 2H), 0.94 (s, 9H), 0.78 (t, *J* = 7.2 Hz, 3H); ¹³**C NMR** (101MHz, CDCl3) δ 172.3, 155.4, 154.8, 134.5, 133.5, 131.6, 131.0, 130.8, 129.8, 128.7, 127.9, 127.9, 127.1, 125.8, 124.9, 123.3, 82.3, 71.9, 40.7, 33.8, 27.6, 12.3; HRMS (ESI) calcd for [C₂₇H₂₉N₃O₄Na]⁺ requires [M + Li]⁺ 482.2056, found 482.2058.




tert-Butyl(5-(3-methoxyphenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate (70); (1-methoxypent-1-en-1-yl)oxy)trimethylsilane (64 mg, 0.34 mmol,) wasaddeddropwisetoamixtureoftert-butyl(E)-2-((3-methoxyphenyl)(methyl)carbamoyl)diazene-1-carboxylate5g(100 mg, 0.34 mmol)and

AgOTf (8.6 mg, 10 mol %) in THF (3.4 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 3 h. After TLC showed consumption of tert-butyl (*E*)-2-((3-methoxyphenyl)(methyl)carbamoyl)diazene-1-carboxylate **5g**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 4 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1×10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAC + Hexane) afforded the title compound (53 mg, 42%) as a colorless Semi-solid.

*V*_{max} /cm⁻¹(neat): 3284, 2966, 1786, 1710, 1454, 1245, 1154

¹**H NMR** (400 MHz, CDCl₃) δ 7.28 (t, *J* = 8.1 Hz, 1H), 6.92 – 6.83 (m, 3H), 6.17 (s, 1H), 3.78 (s, 3H), 3.09 (s, 3H), 2.28 (td, *J* = 13.6, 4.6 Hz, 1H), 2.06 (td, *J* = 13.7, 3.6 Hz, 1H), 1.40 (s, 9H), 1.26 – 1.17 (m, 2H), 0.94 (t, *J* = 7.3 Hz, 3H); ¹³**C NMR** (101MHz, CDCl₃) δ 172.6, 160.1, 155.5, 154.4, 141.8, 137.2, 130.1, 118.6, 113.7, 82.4, 71.7, 55.4, 28.0, 25.0, 16.8, 14.1; HRMS (ESI) calcd for [C₁₉H₂₇N₃O₅Na]⁺ requires [M + Na]⁺ 400.1848, found 400.1854




tert-Butyl (5-(2-chlorophenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate (7p); (1-methoxypent-1-en-1-yl)oxy)trimethylsilane (70 mg, 0.37 mmol,) was added dropwise to a mixture of tert-butyl (E)-2-((2-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5j (112 mg, 0.37 mmol) and AgOTf (9.5 mg, 10 mol %) in THF (3.7 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 3 h. After TLC showed consumption of tert-butyl (*E*)-2-((2-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5j, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise.

After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 4 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc $(3 \times 10 \text{ mL})$. The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (15% EtOAC + Hexane) afforded the title compound (70 mg, 48%) as a colorless solid.

MP: 208-210 °C

*V*_{max} /cm⁻¹(neat): 3277, 2960, 1781, 1690, 1453, 1150

¹**H NMR** (400 MHz, CDCl₃) δ 7.58 – 7.54 (m, 1H), 7.38 – 7.35 (m, 1H), 7.33 – 7.28 (m, 2H), 6.01 (s, 1H), 3.10 (s, 3H), 2.24 (pd, J = 12.9, 3.8 Hz, 2H), 1.36 (s, 9H), 1.25 – 1.14 (m, 2H), 1.00 (t, J = 7.2 Hz, 3H); ¹³**C NMR** (101MHz, CDCl3) δ 172.5, 156.1, 154.8, 132.2, 131.5, 130.7, 130.5, 127.2, 82.3, 70.0, 36.2, 27.9, 25.0, 16.2, 14.1; **HRMS** (ESI) calcd for [C₁₈H₂₄ClN₃O₄Na]⁺ requires [M + Na]⁺ 404.1353, found 404.1355




tert-Butyl (5-(3-chlorophenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate (7q); (1-methoxypent-1-en-1-yl)oxy)trimethylsilane (65 mg, 0.35 mmol,) was added dropwise to a mixture of tert-butyl (*E*)-2-((3-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5d (104 mg, 0.34 mmol) and AgOTf (8.7 mg, 10 mol %) in THF (3.5 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 3 h. After TLC showed consumption of tert-butyl (*E*)-2-((3-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5d, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc

 $(3 \times 10 \text{ mL})$. The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAC + Hexane) afforded the title compound (123 mg, 92%) as a colorless semi-solid.

*V*_{max} /cm⁻¹(neat): 3283, 2969, 1781, 1709, 1454, 1245, 1155, 750

¹**H NMR** (400 MHz, CDCl₃) δ 7.35 (s, 1H), 7.32 – 7.28 (m, 2H), 7.26 (dd, J = 7.0, 1.3 Hz, 1H), 6.41 (s, 1H), 3.10 (s, 3H), 2.24 (td, J = 13.7, 4.5 Hz, 1H), 2.09 (td, J = 14.0, 13.4, 3.9 Hz, 1H), 1.38 (s, 9H), 1.25 – 1.18 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H); ¹³**C NMR** (101MHz, CDCl3) δ 172.2, 155.3, 154.4, 137.8, 134.9, 130.2, 129.0, 126.9, 124.9, 82.7, 71.3, 35.5, 27.9, 25.1, 16.8, 14.0.; HRMS (ESI) calcd for [C₁₈H₂₄ClN₃O₄Na]⁺ requires [M + Na]⁺ 404.1353, found 404.1348




tert-Butyl (3-methyl-2,4-dioxo-5-propyl-5-(3-(trifluoromethyl)phenyl)imidazolidin-1yl)carbamate (7r); (1-methoxypent-1-en-1-yl)oxy)trimethylsilane (64 mg, 0.34 mmol,) was added of dropwise to а mixture tert-butyl (E)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate 5e (113 mg, 0.34 mmol) and AgOTf (8.6 mg, 10 mol %) in THF (3.4 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 3 h. After TLC showed consumption of tert-butyl (E)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate 5e, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and

concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (20% EtOAC + Hexane) afforded the title compound (80 mg, 56%) as a colorless semi-solid.

*V*_{max} /cm⁻¹(neat): 3282, 2968, 1784, 1712, 1454, 1329, 1163, 1127, 752

¹**H NMR** (400 MHz, CDCl₃) δ 7.68 (s, 1H), 7.63 – 7.56 (m, 2H), 7.53 – 7.47 (m, 1H), 6.33 (s, 1H), 3.11 (s, 3H), 2.34 – 2.09 (m, 2H), 1.37 (s, 9H), 1.21 – 1.17 (m, 2H), 0.96 (t, *J* = 7.3 Hz, 3H).; ¹³**C NMR** (101MHz, CDCl3) δ 172.2, 155.3, 154.4, 137.0, 131.4 (q, *J*_{C-F} = 32.3 Hz), 130.3, 126.6 (q, *J*_{C-F} = 272.4 Hz), 125.73 (q, *J*_{C-F} = 3.2 Hz), 123.54 (q, *J*_{C-F} = 3.5 Hz), 82.8, 71.3, 35.9, 27.9, 25.2, 16.9, 14.0; HRMS (ESI) calcd for [C₁₉H₂₄F₃N₃O₄Na]⁺ requires [M + Na]⁺ 438.1617, found 438.1611




tert-Butyl (5-(4-cyanophenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate (7s); (1-methoxypent-1-en-1-yl)oxy)trimethylsilane (67 mg, 0.35 mmol,) was added dropwise to a mixture of tert-butyl (*E*)-2-((4-cyanophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5c (103 mg, 0.35 mmol) and AgOTf (9.0 mg, 10 mol %) in THF (3.5 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2.5 h. After TLC showed consumption of tert-butyl (*E*)-2-((4-cyanophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5c, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 2 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica

chromatography (20% EtOAC + Hexane) afforded the title compound (80 mg, 60%) as a colorless semi-solid.

*V*_{max} /cm⁻¹(neat): 3293, 2923, 2230, 1788, 1711, 1454, 1246, 1156, 843, 752


¹**H NMR** (400 MHz, CDCl₃) δ 7.65 (d, *J* = 8.3 Hz, 2H), 7.56 (d, *J* = 8.3 Hz, 2H), 6.44 (s, 1H), 3.09 (s, 3H), 2.19 (dtd, *J* = 55.3, 14.1, 4.2 Hz, 2H), 1.38 (s, 9H), 1.25-121 (m, 2H), 0.94 (t, *J* = 7.3 Hz, 3H); ¹³**C NMR** (101MHz, CDCl3) δ 171.8, 155.4, 154.5, 141.0, 132.5, 127.7, 118.2, 112.8, 82.9, 71.3, 35.9, 27.9, 25.2, 16.9, 14.0; HRMS (ESI) calcd for [C₁₉H₂₄N₄O₄Na]⁺ requires [M + Na]⁺ 395.1695, found 395.1699



tert-Butyl (3-ethyl-5-(naphthalen-1-yl)-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate (7t); (1-methoxypent-1-en-1-yl)oxy)trimethylsilane (78 mg, 0.41 mmol,) was added dropwise to a mixture of tert-butyl (E)-2-(ethyl(naphthalen-1-yl)carbamoyl)diazene-1-carboxylate **5**i (136 mg, 0.41 mmol) and AgOTf (10.4 mg, 10 mol %) in THF (4.1 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 3 h. After TLC showed consumption of tert-butyl (*E*)-2-(ethyl(naphthalen-1-yl)carbamoyl) diazene-1-carboxylate **5**i, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 3 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1×10 mL), dried over MgSO4 and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (15% EtOAC + Hexane) afforded the title compound (107 mg, 62%) as colourless needles.

*V*_{max} /cm⁻¹(neat): 3274, 2972, 1783, 1708, 1449, 1351, 1159, 731


¹**H NMR** (400 MHz, CDCl₃) δ 7.82 (d, *J* = 7.8 Hz, 2H), 7.66 (d, *J* = 7.3 Hz, 1H), 7.49 (d, *J* = 8.0 Hz, 1H), 7.44 – 7.34 (m, 3H), 5.76 (s, 1H), 3.75 (q, *J* = 7.2 Hz, 2H), 2.44 (td, *J* = 12.9, 4.2 Hz, 1H), 2.32 (dt, *J* = 12.5, 8.1 Hz, 1H), 1.49 – 1.05 (m, 14H), 0.98 (t, *J* = 7.2 Hz, 3H); ¹³**C NMR** (101MHz, CDCl₃) δ ¹³C NMR (101 MHz, CDCl₃) δ 172.9, 155.1, 154.4, 134.5, 131.2, 130.7, 130.0, 129.8, 128.0, 127.1, 125.7, 124.9, 122.3, 82.2, 70.7, 37.2, 34.3, 27.7, 16.4, 14.2, 13.1.; HRMS (ESI) calcd for [C₂₃H₂₉N₃O₄Na]⁺ requires [M + Na]⁺ 434.2056, found 434.2058



tert-Butyl (5-(2-(benzyloxy)ethyl)-5-(3-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1yl)carbamate (7u); (4-(benzyloxy)-1-methoxybut-1-en-1-yl)oxy)trimethylsilane (145 mg, 0.51 mmol.) added dropwise to mixture of (E)-tert-butyl was а 2-((3chlorophenyl)(methyl)carbamoyl)diazenecarboxylate 5d (154 mg, 0.51 mmol) and AgOTf (13.0 mg, 10 mol %) in THF (5.1 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2 h. After TLC showed consumption of (E)-tert-butyl 2-((3chlorophenyl)(methyl)carbamoyl)diazenecarboxylate 5d, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 1.5 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1 \times 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (15% EtOAC + Hexane) afforded the title compound (215 mg, 87%) as a colorless oil.

*V*_{max} /cm⁻¹(neat): 3310, 2978, 2933, 1791, 1714, 1453, 1157


¹**H NMR** (400 MHz, CDCl₃) δ 7.69–7.57 (m, 2H), 7.38 – 7.28 (m, 7H), 6.82 (s, 1H), 4.53 – 4.34 (m, 2H), 3.62–3.39 (m, 2H), 2.96 (s, 3H), 2.54 (br s, 2H), 1.41 (s, 9H);¹³**C NMR** (101MHz, CDCl₃) δ ¹³**C** NMR (101 MHz, CDCl₃) δ 172.0, 156.1, 154.7, 138.4, 136.6, 130.0, 128.9, 128.6, 128.3, 126.9, 124.9, 81.9, 74.2, 70.4, 66.0, 34.4, 28.0, 25.1; HRMS (ESI) calcd for [C₂₄H₂₈ClN₃O₅Na]⁺ requires [M + Na]⁺ 496.1615, found 496.1625



tert-Butyl (5-(2-(benzyloxy)ethyl)-5-(4-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1yl)carbamate (7v); (4-(benzyloxy)-1-methoxybut-1-en-1-yl)oxy)trimethylsilane (142 mg, 0.47 mmol.) added dropwise to a mixture of tert-butyl (E)-2-((4was chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5h (152 mg, 0.47 mmol) and AgOTf (12.8 mg, 10 mol %) in THF (5.0 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 1.5 h. After TLC showed consumption of tert-butyl (E)-2-((4chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate 5h, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 1.5 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine (1 \times 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (15% EtOAC + Hexane) afforded the title compound (183 mg, 76%) as a colorless oil.

*V*_{max} /cm⁻¹(neat): 3310, 2979, 2932, 1790, 1714, 1453, 1156, 1094, 731.

¹**H NMR** (400 MHz, CDCl₃) δ 7.63 (br s, 2H), 7.32 (q, *J* = 5.8, 5.2 Hz, 7H), 6.84 (br s, 1H), 4.52 – 4.33 (m, 2H), 3.64–3.35 (m, 2H), 2.96 (br s, 3H), 2.53 (br s, 2H), 1.41 (s, 9H). ;¹³**C NMR** (101MHz, CDCl₃) δ 172.2, 156.3, 154.8, 136.6, 134.8, 128.8, 128.7, 128.6, 128.3, 128.1, 81.9, 74.3, 70.5, 66.0, 34.4, 28.1, 25.0; HRMS (ESI) calcd for [C₂₄H₂₈Cl₃N₃O₅Na]⁺ requires [M + Na]⁺ 496.1615, found 496.1623




tert-Butyl (5-(2-(benzyloxy)ethyl)-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl) imidazolidin-1-yl)carbamate (7w); 4-(benzyloxy)-1-methoxybut-1-en-1-yl)oxy)trimethyl silane (126 mg, 0.45 mmol,) was added dropwise to a mixture of tert-butyl (*E*)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate **5e** (150 mg, 0.45 mmol) and AgOTf (11.0 mg, 10 mol %) in THF (4.5 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2 h. After TLC showed consumption of tert-butyl (E)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate **5e**, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 1.5 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (1 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (15% EtOAC + Hexane) afforded the title compound (160 mg, 69%) as a colorless oil.

*V*_{max} /cm⁻¹(neat): 3314, 2979, 2869, 1792, 1716, 1328, 1159, 1124.

¹**H NMR** (400 MHz, CDCl₃) δ 8.00 (d, *J* = 61.1 Hz, 2H), 7.58 (d, *J* = 7.6 Hz, 1H), 7.48 (t, *J* = 7.9 Hz, 1H), 7.34 (dt, *J* = 14.6, 7.2 Hz, 5H), 6.91 (s, 1H), 4.52 – 4.36 (m, 2H), 3.61–3.41 (m, 2H), 2.96 (s, 3H), 2.57 (br s, 2H), 1.41 (s, 9H);¹³**C NMR** (101MHz, CDCl3) δ 171.9, 156.2, 154.8, 137.6, 136.5, 131.1 (g, *J* = 32.5 Hz), 130.6, 130.2, 129.2, 128.7, 128.6, 128.3, 125.5,

124.03 (d, J = 272.6 Hz) 123.6, 82.0, 74.3, 70.6, 66.0, 34.9, 28.0, 25.1; HRMS (ESI) calcd for $[C_{25}H_{28}F_3N_3O_5Na]^+$ requires $[M + Na]^+$ 530.1879, found 530.1868




tert-Butyl (5-(2-(benzyloxy)ethyl)-5-(4-cyanophenyl)-3-methyl-2,4-dioxoimidazolidin-1yl)carbamate (7x); (4-(benzyloxy)-1-methoxybut-1-en-1-yl)oxy)trimethylsilane (89 mg, 0.31 mmol,) was added dropwise to а mixture of (E)-tert-butyl 2-((4cyanophenyl)(methyl)carbamoyl)diazenecarboxylate 5c (92 mg, 0.31 mmol) and AgOTf (8.05 mg, 10 mol %) in THF (3.1 mL, 0.1 M) at -78 °C. The reaction was warmed to RT after 10 minutes and stirred at RT for 2 h. After TLC showed consumption of (E)-tert-butyl 2-((4cyanophenyl)(methyl)carbamoyl)diazenecarboxylate 5c, the reaction was cooled to -78 °C and KHMDS (1 M in THF, 3 equiv) was added dropwise. After 10 minutes the reaction was warmed to -20 °C and stirred at -20 °C for 1.5 h. The reaction was quenched with sat. aq. NH₄Cl (10 mL), and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organics were washed with brine $(1 \times 10 \text{ mL})$, dried over MgSO₄ and concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (15% EtOAC + Hexane) afforded the title compound (120 mg, 81%) as a colorless oil.

*V*_{max} /cm⁻¹(neat): 3309, 2978, 2932, 2230, 1791, 175, 1453, 1158, 733.

¹**H NMR** (400 MHz, CDCl₃) δ 7.90 (d, *J* = 4.4 Hz, 2H), 7.65 (d, *J* = 8.8 Hz, 2H), 7.39 – 7.27 (m, 5H), 6.90 (s, 1H), 4.53 – 4.31 (m, 2H), 3.69 – 3.31 (m, 2H), 2.95 (s, 3H), 2.54 (s, 2H), 1.42 (s, 9H).; ¹³**C NMR** (101MHz, CDCl₃) δ ¹³**C** NMR (101 MHz, CDCl₃) δ 171.5, 156.3, 154.9, 141.5, 136.3, 132.4, 128.8, 128.7, 128.4, 127.6, 118.4, 112.6, 82.1, 74.4, 70.8, 65.9, 34.6, 28.1, 25.2; HRMS (ESI) calcd for [C₂₅H₂₈N₄O₅Na]⁺ requires [M + Na]⁺ 487.1957, found 4.87.1967


1.16 General procedure 8: benzyl deprotection

tert-Butyl (5-(3-chlorophenyl)-5-(2-hydroxyethyl)-3-methyl-2,4-dioxoimidazolidin-1yl)carbamate (7y); To a solution of 7u 2 (130 g, 0.27 mol) in .2M MeOH was added 10% Pd(OH)₂/C and the suspension was hydrogenated at atmospheric pressure and ambient temperature for 48 h. Filtration of the catalyst and concentration in vacuo afforded of the desired alcohol 7y, A sample was purified by flash chromatography (hexanes/AcOEt 1:1) to afford pure alcohol 7y as a clear colorless oil (70 mg 66%)




*V*_{max} /**cm**⁻¹(**neat**): 3475, 3298, 2979, 2934, 1787, 1706, 1156 ¹**H NMR** (400 MHz, CDCl₃) δ 7.56 – 7.39 (m, 2H), 7.39 – 7.28 (m, 3H), 6.94 (s, 1H), 3.93 – 3.79 (m, 1H), 3.75 – 3.53 (m, 1H), 3.08 (s, 4H), 2.52–2.47 (m, 2H), 1.42 (s, 9H); ¹³**C NMR** (100 MHz, CDCl₃) δ172.2, 156.2, 155.3, 134.9, 130.1, 129.0, 126.8, 124.8, 82.7, 70.5, 58.4, 35.1, 28.0, 25.3 ; HRMS (ESI) calcd for [C₁₇H₂₂ClN₃O₅Na] requires [M + Na]+ 406.1146, found 406.1159.

1.17 General Procedure 8: Boc-group deprotection:



Trifluoroacetic acid (20% by volume) was added dropwise to a solution of **7** in DCM (0.1 M) at 0 °C. The reaction was the stirred at RT for 4 h and concentrated under reduced pressure to give a crude residue. Reaction mixture was diluted in 3 ml DCM and neutralized with Et₃N and again concentrated under reduced pressure. Purification by flash silica chromatography.




4-(3-Amino-4-benzyl-1-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile (8a); Trifluoroacetic acid (0.42 mL, 20% by volume) was added dropwise to a solution of tert-butyl (5-benzyl-5-(4-cyanophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate **7i** (86 mg, 0.20 mmol, 1 equiv) in DCM (2.1 mL, 0.1 M) at 0 °C. The reaction was the stirred at RT for 4 h. and concentrated under reduced pressure to give a crude residue. Reaction mixture was diluted in 3 ml DCM and neutralized with Et₃N and again concentrated under reduced pressure. Purification by flash silica chromatography (30% EtOAC + Hexane) afforded the *title compound* (60 mg, 92%) as colourless needles.

MP: 188-190 °C

*V*_{max} /cm⁻¹(neat): 3339, 3270, 2925, 1774, 1710, 1608, 1490, 1454, 1058, 757

¹**H NMR** (400 MHz; CDCl₃) δ 7.73 (d, J = 8.7 Hz, 2H), 7.63 (d, J = 8.8 Hz, 2H), 7.31 – 7.26 (m, 3H), 7.17 (dd, J = 7.2, 2.3 Hz, 2H), 3.95 (s, 2H), 3.66 (d, J = 13.6 Hz, 1H), 3.49 (d, J = 13.5 Hz, 1H), 2.77 (s, 3H); ¹³**C NMR** (101 MHz, CDCl₃) δ 171.7, 157.0, 141.9, 132.8, 132.75, 129.4, 128.9, 128.1, 127.3, 118.2, 112.8, 72.8, 40.3, 24.9; **HRMS** (ESI) calcd for [C₁₈H₁₆N₄O₂Na]⁺ requires [M + Na]⁺ 343.1171, found 343.1177



1-Amino-5-benzyl-5-(4-chlorophenyl)-3-methylimidazolidine-2,4-dione (8b); Trifluoroacetic acid (0.25mL, 20% by volume) was added dropwise to a solution of tert-butyl (5-benzyl-5-(4-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate 7j (54 mg, 0.12 mmol, 1 equiv) in DCM (1.25 mL, 0.1 M) at 0 °C. The reaction was the stirred at RT for 4 h


and concentrated under reduced pressure to give a crude residue. Reaction mixture was diluted in 3 ml DCM and neutralized with Et₃N and again concentrated under reduced pressure. Purification by flash silica chromatography (30% EtOAC + Hexane) afforded the *title compound* (32 mg, 78%) as colourless needles.

MP: 219-221 °C


*V*_{max} /cm⁻¹(neat): 3276, 3240, 2987, 1771, 1710, 1494, 1454, 1057, 769

¹**H** NMR (400 MHz, CDCl₃) δ 7.40 –7.39 (m, 3H), 7.29 – 7.24 (m, 4H), 7.16 (dd, J = 7.3, 2.1 Hz, 2H), 3.92 (s, 2H), 3.64 (d, J = 13.5 Hz, 1H), 3.47 (d, J = 13.5 Hz, 1H), 2.75 (s, 3H); ¹³C NMR (100 MHz, CDCl3) δ 172.3, 157.0, 135.1, 134.9, 134.2, 129.4, 129.2, 128.8, 127.9, 127.7, 72.6, 39.9, 24.7; HRMS (ESI) calcd for [C₁₇H₁₆ClN₃O₂Na] requires [M + Na]+ 352.0829, found 352.0832.

1.18 General Procedure 9: Synthesis of bioactive compound analogues:



Carbaldehyde (1.0 equiv) was added to a solution of 1-amino- Hydantoins 6 (1 equiv) and MgSO4 (1.5 equiv) in DCM (0.1 M). The resulting suspension was stirred at RT for 6 h, after which the reaction was concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography.



(E)-4-(4-Benzyl-1-methyl-3-(((5-(4-nitrophenyl)furan-2-yl)methylene)amino)-2,5-

dioxoimidazolidin-4-yl)benzonitrile (9a); 5-(4-Nitrophenyl)furfural (38 mg, 0.17 mmol, 1 equiv) was added to a solution of 4-(3-amino-4-benzyl-1-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile 8a (57 mg, 0.17 mmol, 1 equiv) and MgSO4 (32 mg 1.5 equiv) in DCM (1.7 mL, 0.1 M). The resulting suspension was stirred at RT for 6 h, after which the reaction was concentrated under reduced pressure to give a crude residue. Purification by flash silica chromatography (30% to 100% EtOAc/Petrol) afforded the *title compound* (60 mg, 65%) as yellow needles.

MP: 95-97 °C

*V*_{max} /cm⁻¹(neat): 2921, 1770, 1712, 1599, 1514, 1330, 851, 750

¹**H NMR** (400 MHz; CDCl₃) δ 9.36 (s, 1H), 8.26 (d, *J* = 9.0 Hz, 2H), 7.85 (d, *J* = 9.0 Hz, 2H), 7.73 (d, *J* = 3.0 Hz, 3H), 7.26 – 7.22 (m, 4H), 7.21 – 7.17 (m, 2H), 7.00 (d, *J* = 3.7 Hz, 1H), 6.96 (d, *J* = 3.7 Hz, 1H), 3.80 – 3.68 (m, 2H), 2.73 (s, 3H). ¹³**C NMR** (101 MHz; CDCl₃) ¹³**C** NMR (101 MHz, CHLOROFORM-*D*) δ 170.3, 153.6, 152.9, 151.1, 147.1, 141.8, 141.3, 135.4, 133.1, 132.6, 130.1, 128.6, 128.1, 127.6, 125.8, 124.6, 124.5, 118.3, 115.8, 112.7, 111.1, 110.7, 73.2, 41.5, 24.5 **HRMS** (ESI) calcd for [C₂₉H₂₁N₅O₅Na] requires [M + Na]⁺ 542.1440, found 542.1438.

(E)-5-Benzyl-5-(4-chlorophenyl)-3-methyl-1-(((5-nitrofuran-2-yl)methylene)amino)


imidazolidine-2,4-dione (9b); 5-nitrofuran-2-carbaldehyde (12 mg, 0.085 mmol, 1 equiv) was added to a solution of 1-amino-5-benzyl-5-(4-chlorophenyl)-3-methylimidazolidine-2,4-dione **8b** (30 mg, 0.09 mmol, 1 equiv) and MgSO4 (1.5 equiv) in DCM (0.9 mL, 0.1 M). The resulting suspension was stirred at RT for 6 h, after which the reaction was concentrated under reduced

pressure to give a crude residue. Purification by flash silica chromatography (30% to 100% EtOAc/Petrol) afforded the *title compound* (20 mg, 48%) as a yellow semi-solid.

*V*_{max} /cm⁻¹(neat): 2921, 1772, 1707, 1452, 1347, 1041, 812

¹**H NMR** (400 MHz; CDCl₃) δ 9.76 (s, 1H), 7.44 (d, *J* = 8.8 Hz, 1H), 7.34-7.33 (m, 4H), 7.27 (d, *J* = 3.8 Hz, 1H), 7.22 (dd, *J* = 5.1, 1.8 Hz, 3H), 7.11 (dd, *J* = 7.4, 2.0 Hz, 2H), 3.58 (d, *J* = 13.5 Hz, 1H), 3.42 (d, *J* = 13.4 Hz, 1H), 2.70 (s, 3H).¹³**C NMR** (101 MHz; CDCl₃) δ 178.4, 172.3, 157.0, 151.0, 135.2, 134.9, 134.2, 129.4, 129.2, 128.8, 127.9, 127.7, 118.7, 111.7, 72.6, 39.9, 24.7; **HRMS** (ESI) calcd for [C₂₂H₁₇ClN₄O₅Na] requires [M + Na]⁺ 475.0785, found 475.0765.

1.19 General Procedure 10: N-N bond cleavage:



Aminohydantoin (1.0 equiv.) was dissolved in a 3:1 solution of AcOH and 1 M HCl, followed by addition of NaNO₂ dissolved in water. The reaction mixture was refluxed at 110 °C for 3 h, and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure and the dry residue was exposed to sat. NaHCO₃ (4 mL). The aqueous phase was extracted with EtOAc (3 x 3 mL), the organic extracts were combined and concentrated under reduced pressure to give crude product. The crude material was purified by column chromatography (0% to 100% Et₂O in *n*-pentane) to afford desired product.



3,5-dimethyl-5-(p-tolyl)imidazolidine-2,4-dione

(10a);

tert-butyl (3,5-dimethyl-2,4-dioxo-5-(*p*-tolyl)imidazolidin-1-yl)carbamate **7a** (13.9 mg, 0.042 mmol, 1 equiv.) was dissolved in AcOH (1.5 mL), 1 M HCl (0.5 mL) was then added followed by sodium nitrite (9 mg, 0.13 mmol, 3 equiv.) dissolved in water (0.25 mL). The reaction mixture was refluxed at 110 °C for 3 h, and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure and the dry residue was exposed to sat. NaHCO₃ (4 mL). The aqueous phase was extracted with EtOAc (3 x 3 mL), the organic extracts were combined and concentrated under reduced pressure to give crude product. The crude material was purified by column chromatography (0% to 100% Et₂O in *n*-pentane) to afford the *title compound* (6.1 mg, 67%) as a fine white powder.

 V_{max} /cm⁻¹(film): 3292, 2924, 1778, 1778, 1461; ¹H NMR (400 MHz; CDCl₃) δ 7.38 (d, J = 8.2 Hz, 2H), 7.19 (d, J = 8.2 Hz, 2H), 6.00 (s, 1H), 3.02 (s, 3H), 2.34 (s, 3H), 1.81 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 175.4, 156.7, 138.5, 135.6, 129.6, 125.1, 63.6, 25.4, 24.9, 21.0; HRMS (ESI) calcd for [C₁₂H₁₅N₂O₂] requires [M + H]⁺ 219.1128, found 219.1129.

3,5-dimethyl-5-phenylimidazolidine-2,4-dione




tert-butyl (3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)carbamate **7b** (16.0 mg, 0.05 mmol, 1 equiv.) was dissolved in AcOH (1.5 mL), 1 M HCl (0.5 mL) was then added followed by sodium nitrite (10.4 mg, 0.15 mmol, 3 equiv.) dissolved in water (0.25 mL). The reaction mixture was refluxed at 110 °C for 3 h, and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure and the dry residue was exposed to sat. NaHCO₃ (4 mL). The aqueous phase was extracted with EtOAc (3 x 3 mL), the organic extracts were combined and concentrated under reduced pressure to give crude product. The crude material was purified by column chromatography (0% to 100% Et₂O in *n*-pentane) to afford the *title compound* (8.5 mg, 83%) as a fine white powder.

 V_{max} /cm⁻¹(film): 3268, 1781, 1710, 1459, 1040; ¹H NMR (400 MHz; CDCl₃) δ 7.51 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.36-7.31 (m, 1H), 6.20 (s, 1H), 3.03 (s, 3H), 1.84 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 175.3, 156.8, 138.6, 128.9, 128.5, 125.2, 63.8, 25.6, 24.9; HRMS (+APCI) calcd for [C₁₁H₁₂N₂O₂] requires [M + H]⁺ 205.0972, found 205.0979.

3,5-dimethyl-5-(3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione


(10c);




tert-butyl (3,5-dimethyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl)carbamate **7e** (23.5 mg, 0.06 mmol, 1 equiv.) was dissolved in AcOH (1.5 mL), 1 M HCl (0.5 mL) was then added followed by sodium nitrite (10.4 mg, 0.15 mmol, 2.5 equiv) dissolved in water (0.25 mL). The reaction mixture was refluxed at 110 °C for 3 h, and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure and the dry residue was exposed to sat. NaHCO₃ (4 mL). The aqueous phase was extracted with EtOAc (3 x 3 mL), the organic extracts were combined and concentrated under reduced pressure to give crude product. The crude material was purified by column chromatography (0% to 100% Et₂O in *n*-pentane) to afford the *title compound* (12.6 mg, 76%) as a fine white powder.


*V*_{max} /cm⁻¹(film): 3304, 1782, 1714, 1462, 1330, 1169, 1124; ¹H NMR (400 MHz; CDCl₃) δ 7.81-7.73 (m, 2H), 7.64 (d, J = 7.6 Hz, 1H), 7.56 (t, J = 7.6 Hz, 1H), 5.99 (s, 1H), 3.07 (s, 3H), 1.89 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 174.8, 157.0, 140.0, 131.4 (q, J_{C-F} = 32.8 Hz), 129.6, 129.1, 125.5 (q, J_{C-F} = 3.9 Hz), 124.0 (q, J_{C-F} = 272.5 Hz), 122.2 (q, J_{C-F} = 3.8 Hz), 63.7, 26.3, 25.1; ¹⁹F NMR (377 MHz, CDCl₃) δ -62.5 (s). HRMS (ESI) calcd for [C₁₂H₁₁F₃N₂O₂Na] requires [M + Na]⁺ 295.0665, found 295.0675.

¹H and ¹³C NMR Spectra





N¹,N²-dimethyl-N¹,N²-diphenylhydrazine-1,2-dicarboxamide (S1a)







N¹,N²-dimethyl-N¹,N²-diphenylhydrazine-1,2-dicarboxamide (S1a)







(E)-N¹,N²-dimethyl-N¹,N²-diphenyldiazene-1,2-dicarboxamide (1a)






(*E*)-N¹,N²-dimethyl-N¹,N²-diphenyldiazene-1,2-dicarboxamide (1a)







N¹,N²-dimethyl-N¹,N²-di-p-tolylhydrazine-1,2-dicarboxamide (S1b)










N¹,N²-dimethyl-N¹,N²-di-*p*-tolylhydrazine-1,2-dicarboxamide (S1b)







N¹,N²-dimethyl-N¹,N²-di-*p*-tolyldiazene-1,2-dicarboxamide (1b)







 N^1 , N^2 -Dimethyl- N^1 , N^2 -di-*p*-tolyldiazene-1, 2-dicarboxamide (1b)







N¹,N²-bis(4-cyanophenyl)-N¹,N²-dimethylhydrazine-1,2-dicarboxamide (S1c)







 $N^1, N^2 \mbox{-bis} (4\mbox{-cyanophenyl}) \mbox{-} N^1, N^2 \mbox{-dimethylhydrazine-1,} 2\mbox{-dicarboxamide} (S1c)$







(*E*)-N¹,N²-bis(4-cyanophenyl)-N¹,N²-dimethyldiazene-1,2-dicarboxamide (1c)








 $(E) - N^1, N^2 - bis (4 - cyanophenyl) - N^1, N^2 - dimethyl diazene - 1, 2 - dicarboxamide (1c)$















 $N^1, N^2-bis (4-fluorophenyl)-N^1, N^2-dimethyl hydrazine-1, 2-dicarboxamide\ (S1d)$







(E)-N¹,N²-bis(4-fluorophenyl)-N¹,N²-dimethyldiazene-1,2-dicarboxamide (1d).








$(E) - N^1, N^2 - bis (4-fluorophenyl) - N^1, N^2 - dimethyl diazene - 1, 2 - dicarboxamide (1d).$










































$N^1, N^2-dimethyl-N^1, N^2-bis (3-(trifluoromethyl) phenyl) hydrazine-1, 2-dicarboxamide \ (S1f)$






$N^1, N^2-dimethyl-N^1, N^2-bis (3-(trifluoromethyl) phenyl) hydrazine-1, 2-dicarboxamide \ (S1f)$







$(E) \text{-} N^1, N^2 \text{-} dimethyl \text{-} N^1, N^2 \text{-} bis (3 \text{-} (trifluoromethyl) phenyl) diazene \text{-} 1, 2 \text{-} dicarboxamide$




(1f).





$(E) \text{-} N^1, N^2 \text{-} dimethyl \text{-} N^1, N^2 \text{-} bis (3 \text{-} (trifluoromethyl) phenyl) diazene \text{-} 1, 2 \text{-} dicarboxamide$







N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)hydrazine-1,2-dicarboxamide (S1g)







N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)hydrazine-1,2-dicarboxamide (S1g)






(*E*)-N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)diazene-1,2-dicarboxamide (1g).






(E)-N¹,N²-dimethyl-N¹,N²-di(pyridin-2-yl)diazene-1,2-dicarboxamide (1g).




OMe

(1-Methoxyprop-1-en-1-yl)oxy)trimethylsilane (2a)



OMe OTMS


(1-Methoxyprop-1-en-1-yl)oxy)trimethylsilane (2a)



1H NMR




(1-Methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (2b)







(1-Methoxy-3-phenylprop-1-en-1-yl)oxy)trimethylsilane (2b)




1H NMR




(1-Methoxypent-1-en-1-yl)oxy)trimethylsilane (2c)




13C NMR





(E)-((1-methoxypent-1-en-1-yl)oxy)trimethylsilane (2c)







Methyl 4-(benzyloxy)butanoate S2d







Methyl 4-(benzyloxy)butanoate (S2d)







((4-(Benzyloxy)-1-methoxybut-1-en-1-yl)oxy)trimethylsilane (2d)






((4-(Benzyloxy)-1-methoxybut-1-en-1-yl)oxy)trimethylsilane (2d)







methyl N-(methyl(phenyl)carbamoyl)-N-(3-methyl-3-phenylureido)alaninate (3)










methyl N-(methyl(phenyl)carbamoyl)-N-(3-methyl-3-phenylureido)alaninate (3)







3-(3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)-1-methyl-1-phenylurea (4a)






3-(3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)-1-methyl-1-phenylurea (4a)






3-(3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)-1-methyl-1-phenylurea (4a)




f1 (ppm)


```
HSQC
```




3-(3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)-1-methyl-1-phenylurea (4a)




168 | Page





3-(3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)-1-methyl-1-phenylurea (4a)







3-(3,5-Dimethyl-2,4-dioxo-5-(p-tolyl)imidazolidin-1-yl)-1-methyl-1-(p-tolyl)urea (4b)






3-(3,5-Dimethyl-2,4-dioxo-5-(p-tolyl)imidazolidin-1-yl)-1-methyl-1-(p-tolyl)urea (4b)







1-(4-Cyanophenyl)-3-(5-(4-cyanophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1-




methylurea (4c)





1-(4-Cyanophenyl)-3-(5-(4-cyanophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1-






1-(4-Fluorophenyl)-3-(5-(4-fluorophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1-







1-(4-Fluorophenyl)-3-(5-(4-fluorophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1-




methylurea (4d)




1-(3-Chlorophenyl)-3-(5-(3-chlorophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1-




methylurea (4e)



1-(3-Chlorophenyl)-3-(5-(3-chlorophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1-




methylurea (4e)



3-(3,5-Dimethyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl)-1-methyl-1-


(3-(trifluoromethyl)phenyl)urea (4f)







3-(3,5-Dimethyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl)-1-methyl-1-

(3-(trifluoromethyl)phenyl)urea (4f)







3-(3,5-Dimethyl-2,4-dioxo-5-(pyridin-2-yl)imidazolidin-1-yl)-1-methyl-1-(pyridin-2-




yl)urea (4g)



3-(3,5-Dimethyl-2,4-dioxo-5-(pyridin-2-yl)imidazolidin-1-yl)-1-methyl-1-(pyridin-2-




yl)urea (4g)



3-(5-Benzyl-5-(3-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)-1-(3-


chlorophenyl)-1-methylurea (4h)







3-(5-Benzyl-5-(3-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)-1-(3-

chlorophenyl)-1-methylurea (4h)






3-(5-Benzyl-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl)-1-




methyl-1-(3-(trifluoromethyl)phenyl)urea (4i)




3-(5-Benzyl-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl)-1-

jc/rs77127 rs-179 single pulse decoupled gated NOE 1555,84 (42,77) (42,77) (42,77) (42,77) (13),150 (13),125 - 0.65 0.60 0.55 - 0.50 0.45 - 0.40 0.35 0.30 0.25 - 0.20 0.15 0.10 0.05 - 0.00 ndelikeen interverkeiden alle konstantiitelik MM -0.05 140 130 120 110 100 90 f1 (ppm) 220 70 -20 210 200 180 170 80 20 10 0 -10 190 160 150 60 50 40 30


methyl-1-(3-(trifluoromethyl)phenyl)urea (4i)




3-(5-Benzyl-3-methyl-2,4-dioxo-5-(pyridin-2-yl)imidazolidin-1-yl)-1-methyl-1-(pyridin-




2-yl)urea (4j)




3-(5-Benzyl-3-methyl-2,4-dioxo-5-(pyridin-2-yl)imidazolidin-1-yl)-1-methyl-1-(pyridin-




2-yl)urea (4j)





tert-Butyl 2-(methyl(p-tolyl)carbamoyl)hydrazine-1-carboxylate (S5a)







tert-Butyl 2-(methyl(p-tolyl)carbamoyl)hydrazine-1-carboxylate (S5a)







tert-Butyl (E)-2-(methyl(p-tolyl)carbamoyl)diazene-1-carboxylate (5a)







tert-Butyl (E)-2-(methyl(p-tolyl)carbamoyl)diazene-1-carboxylate (5a)







tert-Butyl 2-(methyl(phenyl)carbamoyl)hydrazine-1-carboxylate (S5b)







tert-Butyl 2-(methyl(phenyl)carbamoyl)hydrazine-1-carboxylate (S5b)







tert-Butyl (*E*)-2-(methyl(phenyl)carbamoyl)diazene-1-carboxylate (5b).







tert-Butyl (E)-2-(methyl(phenyl)carbamoyl)diazene-1-carboxylate (5b).







tert-Butyl 2-((4-cyanophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5c)







tert-Butyl 2-((4-cyanophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5c)







tert-Butyl (E)-2-((4-cyanophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5c).







tert-Butyl (E)-2-((4-cyanophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5c).







tert-Butyl 2-((3-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (85d)







tert-Butyl 2-((3-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (85d)







tert-Butyl (E)-2-((3-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5d).







tert-Butyl (E)-2-((3-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5d).







tert-Butyl 2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)hydrazine-1-carboxylate






tert-Butyl 2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)hydrazine-1-carboxylate







tert-Butyl (E)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate




(5e).




tert-Butyl (E)-2-(methyl(3-(trifluoromethyl)phenyl)carbamoyl)diazene-1-carboxylate










tert-Butyl 2-(methyl(pyridin-2-yl)carbamoyl)hydrazine-1-carboxylate (S5f)







tert-Butyl 2-(methyl(pyridin-2-yl)carbamoyl)hydrazine-1-carboxylate (S5f)







tert-Butyl (E)-2-(methyl(pyridin-2-yl)carbamoyl)diazene-1-carboxylate (5f).







tert-Butyl (E)-2-(methyl(pyridin-2-yl)carbamoyl)diazene-1-carboxylate (5f).






tert-Butyl 2-((3-methoxyphenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5g)








tert-Butyl 2-((3-methoxyphenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5g)




1H NMR













tert-Butyl (E)-2-((3-methoxyphenyl)(methyl)carbamoyl)diazene-1-carboxylate (5g).







tert-Butyl 2-((4-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5h)







tert-Butyl 2-((4-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5h)







tert-Butyl (E)-2-((4-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5h).







tert-Butyl (E)-2-((4-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5h).







Methyl(naphthalen-1-yl)carbamic chloride SS5i







Methyl(naphthalen-1-yl)carbamic chloride (SS5i)







tert-Butyl 2-(ethyl(naphthalen-1-yl)carbamoyl)hydrazine-1-carboxylate (85i)







tert-Butyl 2-(ethyl(naphthalen-1-yl)carbamoyl)hydrazine-1-carboxylate (S5i)







tert-Butyl (E)-2-(ethyl(naphthalen-1-yl)carbamoyl)diazene-1-carboxylate (5i).







tert-Butyl (E)-2-(ethyl(naphthalen-1-yl)carbamoyl)diazene-1-carboxylate (5i).







(2-Chlorophenyl)(methyl)carbamic chloride (SS5j)







(2-Chlorophenyl)(methyl)carbamic chloride (SS5j)







tert-Butyl 2-((2-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5j)







tert-Butyl 2-((2-chlorophenyl)(methyl)carbamoyl)hydrazine-1-carboxylate (S5j)







tert-Butyl (E)-2-((2-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5j).








tert-Butyl (E)-2-((2-chlorophenyl)(methyl)carbamoyl)diazene-1-carboxylate (5j).















tert-Butyl 2-(1-methoxy-1-oxopropan-2-yl)-2-(methyl(*p*-tolyl)carbamoyl)hydrazinecarboxylate (6)







tert-Butyl (3,5-dimethyl-2,4-dioxo-5-(p-tolyl)imidazolidin-1-yl)carbamate (7a)







tert-Butyl (3,5-dimethyl-2,4-dioxo-5-(p-tolyl)imidazolidin-1-yl)carbamate (7a)







tert-Butyl (3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)carbamate (7b)







tert-Butyl (3,5-dimethyl-2,4-dioxo-5-phenylimidazolidin-1-yl)carbamate (7b)







tert-Butyl (5-(4-cyanophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)carbamate (7c)







tert-Butyl (5-(4-cyanophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)carbamate (7c)






tert-Butyl (5-(3-chlorophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)carbamate (7d)







tert-Butyl (5-(3-chlorophenyl)-3,5-dimethyl-2,4-dioxoimidazolidin-1-yl)carbamate (7d)




1H NMR




tert-Butyl (3,5-dimethyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-




yl)carbamate (7e)




tert-Butyl (3,5-dimethyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-




yl)carbamate (7e)





tert-Butyl (3,5-dimethyl-2,4-dioxo-5-(pyridin-2-yl)imidazolidin-1-yl)carbamate (7f)







tert-Butyl (3,5-dimethyl-2,4-dioxo-5-(pyridin-2-yl)imidazolidin-1-yl)carbamate (7f)







tert-Butyl (5-benzyl-3-methyl-2,4-dioxo-5-(p-tolyl)imidazolidin-1-yl)carbamate (7g)







tert-Butyl (5-benzyl-3-methyl-2,4-dioxo-5-(p-tolyl)imidazolidin-1-yl)carbamate (7g)






tert-Butyl (5-benzyl-5-(3-methoxyphenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate







tert-Butyl (5-benzyl-5-(3-methoxyphenyl)-3-methyl-2,4-dioxoimidazolidin-1-




yl)carbamate (7h)





tert-Butyl (5-benzyl-5-(4-cyanophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate







tert-Butyl (5-benzyl-5-(4-cyanophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate







tert-Butyl (5-benzyl-5-(4-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate






tert-Butyl (5-benzyl-5-(4-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate







tert-Butyl (5-benzyl-5-(3-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate




210 | Page




tert-Butyl (5-benzyl-5-(3-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-yl)carbamate




211 | P a g e




tert-Butyl (5-benzyl-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-




yl)carbamate (7l)




tert-Butyl (5-benzyl-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-







tert-Butyl (5-benzyl-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl)




carbamate (7m)




tert-Butyl (5-benzyl-3-methyl-2,4-dioxo-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-yl)




carbamate (7m)





 $tert-{\it Butyl}\ (5-benzyl-3-methyl-5-(naphthalen-1-yl)-2, 4-dioxoimidazolidin-1-yl) carbamate$






 $tert-{\it Butyl}\ (5-benzyl-3-methyl-5-(naphthalen-1-yl)-2, 4-dioxoimidazolidin-1-yl) carbamate$







tert-Butyl (5-(3-methoxyphenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate




(70)




 $tert \hbox{-} Butyl \ (5-(3-methoxyphenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl) carbamate$




219 | Page




tert-Butyl (5-(2-chlorophenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate




220 | Page




tert-Butyl (5-(2-chlorophenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate




(7p)




tert-Butyl (5-(3-chlorophenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate







tert-Butyl (5-(3-chlorophenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate




(7q)




tert-Butyl (3-methyl-2,4-dioxo-5-propyl-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-




yl)carbamate (7r)




tert-Butyl (3-methyl-2,4-dioxo-5-propyl-5-(3-(trifluoromethyl)phenyl)imidazolidin-1-




yl)carbamate (7r)




tert-Butyl (5-(4-cyanophenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate






tert-Butyl (5-(4-cyanophenyl)-3-methyl-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate





(7s)




tert-Butyl (3-ethyl-5-(naphthalen-1-yl)-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate

(7t)







tert-Butyl (3-ethyl-5-(naphthalen-1-yl)-2,4-dioxo-5-propylimidazolidin-1-yl)carbamate




1H NMR




tert-Butyl (5-(2-(benzyloxy)ethyl)-5-(3-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-




yl)carbamate (7u)




tert-Butyl (5-(2-(benzyloxy)ethyl)-5-(3-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1-




yl)carbamate (7u)




tert-Butyl (5-(2-(benzyloxy)ethyl)-5-(4-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1yl)carbamate (7v)









tert-Butyl (5-(2-(benzyloxy)ethyl)-5-(4-chlorophenyl)-3-methyl-2,4-dioxoimidazolidin-1yl)carbamate (7v)






tert-Butyl (5-(2-(benzyloxy)ethyl)-3-methyl-2,4-dioxo-5-(3-


(trifluoromethyl)phenyl)imidazolidin-1-yl)carbamate (7w)







tert-Butyl (5-(2-(benzyloxy)ethyl)-3-methyl-2,4-dioxo-5-(3-


(trifluoromethyl)phenyl)imidazolidin-1-yl)carbamate (7w)







tert-Butyl (5-(2-(benzyloxy)ethyl)-5-(4-cyanophenyl)-3-methyl-2,4-dioxoimidazolidin-1yl)carbamate (7x)






tert-Butyl (5-(2-(benzyloxy)ethyl)-5-(4-cyanophenyl)-3-methyl-2,4-dioxoimidazolidin-1yl)carbamate (7x)






tert-Butyl (5-(3-chlorophenyl)-5-(2-hydroxyethyl)-3-methyl-2,4-dioxoimidazolidin-1-




yl)carbamate (7y)





tert-Butyl (5-(3-chlorophenyl)-5-(2-hydroxyethyl)-3-methyl-2,4-dioxoimidazolidin-1-


yl)carbamate (7y)




















4-(3-Amino-4-benzyl-1-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile (8a)







1-Amino-5-benzyl-5-(4-chlorophenyl)-3-methylimidazolidine-2,4-dione (8b)






1-Amino-5-benzyl-5-(4-chlorophenyl)-3-methylimidazolidine-2,4-dione (8b)







(E)-4-(4-Benzyl-1-methyl-3-(((5-(4-nitrophenyl)furan-2-yl)methylene)amino)-2,5-




dioxoimidazolidin-4-yl)benzonitrile (9a)




(E)-4-(4-Benzyl-1-methyl-3-(((5-(4-nitrophenyl)furan-2-yl)methylene)amino)-2,5-




dioxoimidazolidin-4-yl)benzonitrile (9a)




(E)-5-Benzyl-5-(4-chlorophenyl)-3-methyl-1-(((5-nitrofuran-2-yl)methylene)amino)




imidazolidine-2,4-dione (9b)




(E)-5-Benzyl-5-(4-chlorophenyl)-3-methyl-1-(((5-nitrofuran-2-yl)methylene)amino)



imidazolidine-2,4-dione (9b)





¹H NMR of 10c

